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Abstract
The world of basic science is a world of minutia; it boils down to improving even a
fraction of a percent over the baseline standard. It is a domain of peer reviewed fractions
of seconds and the world of squeezing every last ounce of efficiency from a processor, a
storage medium, or an algorithm. The field of health data is based on extracting
knowledge from segments of data that may improve some clinical process or practice
guideline to improve the time and quality of care. Clinical informatics and knowledge
translation provide this information in order to reveal insights to the world of improving
patient treatments, regimens, and overall outcomes.
In my world of minutia, or basic science, the movement of blood served an integral role.
The novel detection of sound reverberations map out the landscape for my research. I
have applied my algorithms to the various anatomical structures of the heart and artery
system. This serves as a basis for segmentation, active contouring, and shape priors. The
algorithms presented, leverage novel applications in segmentation by using anatomical
features of the heart for shape priors and the integration of optical flow models to
improve tracking. The presented techniques show improvements over traditional methods
in the estimation of left ventricular size and function, along with plaque estimation in the
carotid artery.
In my clinical world of data understanding, I have endeavoured to decipher trends in
Alzheimer’s disease, Sepsis of hospital patients, and the burden of Melanoma using
mathematical modelling methods. The use of decision trees, Markov models, and various
clustering techniques provide insights into data sets that are otherwise hidden. Finally, I
demonstrate how efficient data capture from providers can achieve rapid results and
actionable information on patient medical records. This culminated in generating studies
on the burden of illness and their associated costs.
A selection of published works from my research in the world of basic sciences to
clinical informatics has been included in this thesis to detail my transition. This is my
journey from one contented realm to a turbulent one.
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“Yesterday I was clever, so I wanted to change the world. Today I am wise, so I am
changing myself.” – Rumi
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Preface
Throughout this thesis, several published articles have been presented to represent my
transition from basic sciences research to clinical informatics research. In one way or
another, the techniques described in each article build on each other, and have fostered the
nurturing of my skills to continue into the world of clinical informatics.
Though some of these works were published earlier on during my research tenure, my
intention is to demonstrate that I would not have accomplished or ended up at my current
research state without such prior works.
Please note, this is not a complete list of my published works during this period.
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Chapter 1
1 Basic Science Introduction
“A worker in basic scientific research is motivated by a driving curiosity about the unknown.
When his explorations yield new knowledge, he experiences the satisfaction of those who first
attain the summit of a mountain or the upper reaches of a river flowing through unmapped
territory. Discovery of truth and understanding of nature are his objectives. His professional
standing among his fellows depends upon the originality and soundness of his work.”
National Science Foundation, Annual Report, 1953 – “What is Basic Research”
My journey begins here.

Basic science research (i.e. pure or fundamental research) is a methodical study directed
toward greater knowledge or understanding of the fundamental aspects of phenomena. [1] It
has a very measurable and practical end goal, without a specific product in mind. It is
founded in curiosity where an application or particular problem can be solved or improved
upon. This is the type of research where foundations are layered upon and advancement of
fundamental parts are achieved. An unexpected discovery is many a times the catalyst for
basic science research, and the flood gates of systemic research follows.

1.1 Heart Disease and Stroke Overview
Computer imaging and imaging technologies were my primary interest. I have continued my
exploration of the cardiovascular system, which was the logical progression to my earlier
research endeavours. [2][3][4] Being extremely interested in specific cardiovascular diseases
and treatment methodologies, I set out to understand the nature of imaging, and specific
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testing on the heart. In 1992, the Advisory Board of the International Heart Health
Conference stated: “Cardiovascular disease is largely preventable. We have the scientific
knowledge to create a world in which most heart disease and stroke could be eliminated.”
[5] I wanted to be a part of that initiative.
Heart disease and stroke cost the Canadian economy more than $20.4 billion every year, in
physician services, hospital costs, lost wages and decreased productivity. [6] Sadly, one in
three deaths in Canada is still due to heart disease and stroke alone. [6] In order to help
reduce such costs, the use of modern day technologies need to be developed in order to help
simplify and reduce a medical practitioner’s daily workload. The advent in ultrasonography
is one such technique.
The assessment of cardiac function has been a major area of interest in the medical field.
Normal heart function includes pumping chambers (known as ventricles) which regulate the
systemic and pulmonary circulation systems by delivering blood to the proper areas. [7]
Abnormal heart function in the left ventricle (LV) can be caused by systolic dysfunction, (i.e.
the reduction in the ability to contract) or diastolic dysfunction (i.e. the inability to fill
efficiently). Along with function, other various heart structures (e.g. valves and tissues) may
fail at any point causing cardiomyopathies, endangering the life of the host individual.
Fortunately, many myopathies are treatable (with medication, implanted pacemakers,
defibrillators, or ventricular assist devices) given early detection. Standard clinical metrics
such as an ejection fraction (i.e. the fraction of blood pumped out of a ventricle with each
heart beat) plays a large role in such detections. [7]

1.2 Relevant Imaging Technologies
Several imaging modalities of cardiac function have each evolved independently in order to
measure left ventricular function, various valve analysis and myocardial perfusion for various
patients and research studies. These include:
Cardiovascular Magnetic Resonance (CMR) [8] – a powerful medical imaging modality
due to its non-invasiveness and remarkable flexibility. CMR is able to produce highresolution in vivo images of vascular anatomy and to a lesser degree measure blood flow
rates through vessels. Though CMR’s current limitations include: 1) low accessibility, due to
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significant costs for setup and operation, 2) poor out of plane spatial resolution, and 3)
lengthy procedure times (often up to an hour depending on the scanning protocol)
Cardiac Computed Tomography (CT) [9] – extended the life of the traditional x-ray
imaging techniques by providing tomographical images rather than projections of anatomy.
CT imaging eliminates the superposition of multiple vessels problem, found in traditional xray measurements. However, pronounced coronary calcification, especially in patients with
high heart rates, and motion artifacts can render images difficult or even impossible to
interpret. Patients with arterial fibrillation or other arrhythmias cannot be evaluated.
Cardiac Positron Emission computed Tomography (PET) [10] – is a nuclear medicine
technique that can produce a functional image map of the heart. Generally, a tracer
(radioactive isotope) is injected into the body and tracked by a scanner. Analysis reconstructs
the flow of the isotope throughout the various heart chambers and generates a threedimensional map. This imaging technique not only shares many of the limitations of CT but
is also invasive and expensive to administer.
Echocardiography [11, 12] – involves the transmission and reception of directional
ultrasound (acoustical) waves in order to form image data of the heart, (also known as
cardiac ultrasound). Echocardiography can produce accurate assessment of blood velocity
and cardiac tissue at any arbitrary point using pulsed or continuous ultrasound waves. This
allows for various cardiac valve and function assessment.

1.3 Ultrasound Focus
All of my basic science research has focused on the use of ultrasound technologies as it
provides an inexpensive non-invasive means for visualizing various tissues within the human
body. However, these visualizations tend to be filled with speckle noise and other artifacts,
due to the sporadic nature of high frequency sound waves. Many techniques for segmenting
ultrasound images have been introduced in order to deal with these problems [13, 14, 15, 16,
17, 18].
Several types of US (e.g., Doppler, B-mode, Pulse Inversion, Harmonic, etc) have proven to
be useful tools for medical imagery [16][19]. Doppler US measures the Doppler shift
between impinging ultrasound waves that are scattered by red blood cells [17]. This
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technique can be used to determine the direction and speed of blood flow between vessels
within the heart cavity. Though this can be used to estimate peak systolic and diastolic
velocities, these flow based measurements suffer from problems concerning intra- and interoperator variability due to the turbulent nature of the flow within the heart. A B-mode
(brightness mode) US image is a two-dimensional tomographic display composed of bright
dots by measuring the time-resolved reflected power of impinging ultrasound waves upon
tissues and vessels in the body [20]. The echo amplitude determines the brightness of each
dot which is sensitive to the boundaries between fluid filled structures, such as blood vessels
and surrounding tissues. High-resolution B-mode ultrasonography has greatly improved the
ability to identify problematic regions in the heart over other techniques (e.g. PET, CMR,
CT) without risking the patient’s well-being [12].
In the first integrated article, which has been cited 18 times as of the submission of this
thesis, “Carotid ultrasound Segmentation using DP Active Contours” [21], two proposed
alterations to the dynamic programming parametric active contour model (or snake) are
introduced. The first alteration allows the snake to converge to the one-response result of a
modified Canny edge detector. The second provides a function that allows a user to pre-set apriori knowledge about a given object being detected, by means of curve fitting and energy
modification. The results yield accurate segmentations of cross-sectional transverse carotid
artery ultrasound images that are validated by independent clinical radiologists. Utilizing the
proposed alterations leads to a reduction of clinician interaction time while maintaining an
acceptable level of accuracy for varying measures such as percent stenosis.
In the second integrated article which has been cited 15 times as of the submission of this
thesis, “Active Contours with Optical Flow and Primitive Shape Priors for
Echocardiographic Imagery” [22] we propose the use of a new external energy for a Gradient
Vector Flow (GVF) snake, consisting of the optical flow data of moving heart structures (i.e.
the perceived movement). This new external energy provides more information to the active
contour model to combat noise in moving sequences. An automated primitive shape prior
mechanism is also introduced, which further improves the results when dealing with
especially noisy echocardiographic image cines. Results were compared with that of expert
manual segmentations yielding promising sensitivities and system accuracies.
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In the third integrated article which was only cited 2 times as of the submission of this thesis,
however this has been published as a book chapter as well, “SRAD, Optical Flow and
Primitive Prior based Active Contours for Echocardiography” [23] we build on the previous
work and include a new operator in the external energy to significantly improve the results.
This energy consists of optical flow estimates of heart sequences along with the use of a
speckle reducing anisotropic diffusion (SRAD) operator. Furthermore, an automatic
primitive shape prior algorithm was employed to further improve the results and regularity of
the snake, when dealing with especially speckle laden echocardiographic images. Results
were compared with expert-defined segmentations yielding better sensitivity, precision rate
and overlap ratio than the standard GVF model.
This selection of works concludes my basic science research and allows me to leap frog into
the world of informatics research in the clinical domain.

1.4 Selection of Papers
The selection of these works demonstrates a growth in the presented techniques and how the
development of the segmentation pipeline evolved over time. The additional works that were
not selected in the basic science domain presented further cases and testing sets at
conferences. The presented works have been used as a foundation in other research projects
by external parties. We have provided the citation count for each of the works as depicted
above. The first article presents the segmentation pipeline with alterations that help to
segment borders in ultrasound images. The second builds on these techniques to provide
inter-cine information to remove more noise and improve the segmentation accuracy. The
final article adds additional algorithms to in noise reduction in order to garner further
accuracy from the pipeline. All data was collected from volunteers and imaged under
standard clinical practices in order to ensure developed algorithms could be used on patient
supplied images.
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Chapter 2 - Article 1
2 Carotid Ultrasound Segmentation using DP Active Contours*
Abstract: Ultrasound provides a non-invasive means for visualizing various tissues within
the human body. However, these visualizations tend to be filled with speckle noise and other
artifacts, due to the sporadic nature of high frequency sound waves. Many techniques for
segmenting ultrasound images have been introduced in order to deal with these problems.
One such technique is the active contouring.
In this paper, two proposed alterations to the dynamic programming parametric active
contour model (or snake) are introduced. The first alteration allows the snake to converge to
the one-response result of a modified Canny edge detector. The second provides a function
that allows a user to preset a-priori knowledge about a given object being detected, by means
of curve fitting and energy modification. The results yield accurate segmentations of crosssectional transverse carotid artery ultrasound images that are validated by an independent
clinical radiologist. Utilizing the proposed alterations leads to a reduction of clinician
interaction time while maintaining an acceptable level of accuracy for varying measures such
as percent stenosis.
Keywords: Ultrasound Imaging, Carotid Stenosis, Image Segmentation, Active Contour
Models

2.1 Introduction
Carotid ultrasound (US) is considered an inexpensive non-invasive clinical procedure for
evaluating many carotid artery diseases [10]. It provides flexibility for offline review of

*

A version of this chapter has been published: Ali K. Hamou, Said Osman and Mahmoud R. El-Sakka,
“Carotid Ultrasound Segmentation Using DP Active Contours”, International Conference on Image Analysis
and Recognition (ICIAR), 2007, LNCS 4633, pp. 961-971.
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patient records efficiently, i.e., the US images can be acquired by a clinician and stored for
later testing and analysis, with minimal user input. A brightness-mode (or B-mode) US
image is one of the two major types of US used on the carotid. This study will primarily
focus on B-mode images since it provides an adequate means for an efficient clinical
measurement of patients that are susceptible to plaque accumulation (whether from diet,
genetics, obesity, etc). A B-mode US image is made up of a two-dimensional ultrasound
display composed of bright pixels representing the ultrasound echoes and reverberations [16].
The echo amplitude determines the brightness of each pixel.
A high degree of carotid artery stenosis, which can be used as a pre-clinical disease marker,
is an early indicator of a possible stroke. Stenosis is the abnormal narrowing of a blood
vessel. It is generally caused by plaque build up [10]. Atheromatous plaque is an
accumulation of fatty deposits that form inflamed patches within the inner lining of the
arteries. In ultrasound images, hard (calcified) and soft plaque are represented as a range of
high and low contrast pixels. However, these plaque areas have virtually the same levels of
contrast to the surrounding soft tissue due to the lack of texture resolution and the high levels
of noise inherent to US images. This poses many difficult problems for plaque and lumen
detection algorithms since experienced clinicians subjectively dictate the amount of plaque
build up based on knowledge of image structures and prior training.
Boundary detection is one of the most important elements of computer vision. Many
techniques have been introduced to accomplish this task. One such example is an active
contour model. Kass el al. [11] first proposed the original active contour model, also
commonly known as a snake or a deformable model. In their formulation, image
segmentation was posed as an energy minimization problem.
Active contours treat the surface of an object as an elastic sheet that stretches and deforms
when external and internal forces are applied to it. These models are physically-based, since
their behaviour is designed to mimic the physical laws that govern real-world objects [8].
This model helps solve the problems of edge based segmentation techniques, such as
bleeding of the contour and unstable borders as exhibited in [1].
Active contour models have two inherent problems:
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•

the proximity limitations of attaining a true boundary, especially when coupled with
poor initialization plots

•

the inability of traversing boundary concavities due to strong surface tension in the
curve.

The former is rarely an issue in the medical arena since clinicians are generally accepted as
experts. Conversely, several studies have been conducted to overcome the latter, while also
improving the accuracy and the speed of the original design. Of these are Dynamic
Programming (DP) [5], level sets [18] and Gradient Vector Flow (GVF) models [19] just to
name a few.
The DP parametric active contour provides an efficient algorithm to quickly attain a desired
curve. In this study, we have chosen this model for this attractive feature. Within this model,
we propose a new external energy to be made up of two distinct elements. The first is to be
composed of an edge map resulting from a modified Canny edge detector. Canny edge
detection will maintain the one-edge response and the local connectedness property of an
image, whereas the active contour will ensure that our entire energy is minimized over the
detected border [5]. The second will be the curve-fitted data built upon the user’s initial plots
and incorporated into the energy. This will amplify the amount of knowledge received from
the clinician in acquiring a desired boundary.
The proposed segmentation algorithm is used to extract a cross-sectional area of the carotid
artery at two specified positions (see Section 2.3), which is then used to calculate a percent
stenosis that is less prone to user bias between clinicians. It is important to note that
measuring the percent stenosis is usually done by manually estimating the diameter of the
carotid via catheter angiography. This introduces large user bias into the calculations, while
being quite costly from a clinician’s time standpoint.
Abolmaesumi et al. [4] designed an efficient Kalman-star algorithm to estimate the location
of the arterial wall. However, their algorithm still crosses the external boundaries of the wall
due to the use of first degree gradient estimation.
Mao et al. [13] used a contour probability distribution (CPD) function in order to evaluate the
accuracy of their segmentation algorithm. Their algorithm employed entropy mapping and
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morphological operations based on gray-level values within an image. These mappings create
an accurate identification of the arterial wall. However they are strenuous on computer
systems resulting in long execution times.
A class of schemes [1,2,3,9] for carotid artery contour extraction that are based on the use of
local edge detection techniques are proposed. However, these schemes are used globally
throughout an image, and hence lack localization. All of these techniques are susceptible to
leaking (or contour bleeding), especially if the image quality is not suitable. Hence other
means are needed to properly segment the carotid and calculate its percent stenosis.
The rest of this paper is organized as follows. In Section 2, the proposed scheme is presented.
The results of the scheme are shown in Section 3, and Section 4 contains conclusions.

2.2 System and Methods
2.2.1 External Energy Formulation
A snake is an energy minimization problem. Its energy is represented by two forces (internal
energy, Ein, and external energy, Eex) which work against each other. The total energy should
converge to a local minimum – in the perfect case – at the desired boundary. The snake is
defined as X(s), where s belongs to the interval [0,1]. Hence, the total energy to be minimized
to give the best fit between a snake and a desired object shape is:
Total Energy =



s 1
s 0

{Ein ( X ( s ))  Eex ( X ( s ))}ds

(1)

The internal energy would force the curve to be smooth (by incorporating both elasticity and
stiffness); whereas the external energy would force the curve towards image structures
(image edges). The internal energy of the active contour formulation is further defined as:
 d 2 X ( s) 
 dX ( s ) 


Ein ( X ( s ))    




2
 ds 
 ds 
2

2

(2)

where α and β are the weights of elasticity and stiffness, respectively. The first order term
makes the snake’s surface act like a membrane. The weight α controls the tension along the
spine (stretching a balloon or elastic band). The second order term makes the snake act like a
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thin plate. The weight β controls the rigidity of the spine (bending a thin plate or wire) [8].
We define our external energy as:
Eex = γ  Canny(f(x,y) ,σ, l, u) + τ  Shape(X(s))

(3)

where γ and τ are the weights for the two proposed external energy elements, Canny and prior
shape knowledge, respectively, and f(x,y), σ, l, and u, represent the original image and the
parameters for the Canny operator, being the degree of Gaussian blur, a lower threshold and
an upper threshold. The weights γ and τ are important factors in governing whether the
clinician’s knowledge or the modified Canny edge map takes precedence in the converging
snake model.
In general, active contour internal and external energies need to be balanced properly in order
to converge to the desired edge in question. In order to properly tune the given curve with the
proper weights, values were adjusted until the snake converged to the edges chosen by the
radiologist. Samples were taken on both normal and diseased images in order to properly
validate the curve with the chosen weights. Initially, equal weights were assigned to each
energy. Gradually weights were shifted until acceptable edge convergence was achieved
across several datasets. The weights α, β, γ and τ were set to 0.09, 0.01, 0.5, and 0.4,
respectively. This is justified for the US images, since the modified Canny edge detector and
the a-priori knowledge resides in the external energy formulation. Hence more weight should
be shifted towards the external energy.

2.2.2 Canny Edge Detection
The Canny algorithm will first smooth the data (by means of a Gaussian filter) in order to
remove speckle noise. Then edge detection is performed. Canny optimizes edge-response
with respect to three criteria:
•

Detection: real edges should not be missed, and false edges should be avoided.

•

Location: the edge response should lie as close as possible to its true location.

•

One-response: a true edge should not give rise to more than one response.

Canny is particularly susceptible to input parameters [6]. These parameters allow for finetuning of the edge-detection mechanism, permitting the user to acquire the desired results on
an image data set. Canny uses a technique called “non-maximum suppression” that relies on
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two thresholding values (lower and upper). The lower defines a threshold for all points that
should not be considered lying on an edge. The upper defines a threshold for all the points
guaranteed to be lying on an edge [6].
To emphasize the main edges in an image, the two thresholds should be large. To find the
details of an image, their value should be small. The Canny edge detector was applied with
increasing lower and upper thresholds and the resulting images were probed where expected
edges should exist within the US images. Canny recommends that the lower threshold should
be one third the amount of the upper threshold. Our trials are consistent with the
recommended values yielding a 0.2 lower threshold and a 0.6 upper threshold. We also found
these thresholds reduce the creation of false edges due to speckle noise in the image without
degradation.

(a)

(b)

(c)

(d)

Figure 2-1: Example of Edge detection. (a) Original carotid US image. (b) Canny edge
detected binary image (c) Modified Canny edge detected grayscale image (d) Distance
transformed modified Canny edge detected image
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Modification to the Canny edge detection algorithm was necessary in order to more
accurately integrate this measure into the external energy. The standard Canny edge detector
outputs all edges as a binary result. Each point that is lying on a Canny detected edge will not
have the same weight following detection; rather it will be replaced with its relative gradient.
Figure 2-1(a) shows an example of a carotid artery US image. Figure 2-1(b) shows the US
image following the application of a normal Canny edge detector. The result is a binary
image with all points having the same weight. Figure 2-1(c) shows the modified Canny edge
detector where each point has a designated weight associated with its gradient – hence a gray
scale image. Each gradient point is incorporated into the external energy by means of a
Manhattan distance transform [17], as shown in Figure 2-1(d). The Manhattan distance
transform provides a set of gray level intensities that show the distance to the closest
boundary from each point. This provides a path to a better local minimum by avoiding small
hazards of unwanted noise. The Manhattan distance of the modified Canny edge map was
sufficient for the purpose of this study due to its simplicity and elegance of implementation.
The energy will also converge such that it will mimic the behaviour of GVF snakes, since the
curve will be forced into boundary concavities.

2.2.3 A-Priori knowledge
It is desirable to incorporate some means of shape to the model without directly involving the
user. Automatic shape detection takes place on the initial plots positioned by the user. This
would force the active contour to converge closer to the user’s first delineated points. This is
especially useful in the medical arena where a specialist or technician has a clear
understanding of the underlying structure being detected, such as a liver, an artery, or a heart.
Traditional shape priors in snake models tend to take place in the internal energy [12].
However, this knowledge has been incorporated into the external energy in order to influence
the shape and the positional information as well – since it is readily available from the user.
This shape and position information will also be represented by the Manhattan distance
transform in order to properly integrate it within the external energy.
For carotid images, the prior was set to ellipses. A least squares ellipse fitting technique is
performed on the points of the initial contour. The initial ellipse is defined using the initial
contour placement points of the snake. Continual refinement takes place by attempting to
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minimize the geometric error of a series of approximating curves to the initial points. This
process continues until a curve with minimal deviation from all snake contour points is
found.
Figure 2-2(a) and Figure 2-2(b) shows the active contour being used without and with a-prior
knowledge, respectively. Figure 2-2(a) depicts an improper segment of the boundaries, most
likely due to poor visualization in the lower region of the image. Figure 2-2(b) takes the same
initial plots and builds knowledge around the data by ellipse fitting in order to prevent the
collapse of the curve and improve alignment with the true lumen.

2.2.4 Clinical Metrics
The desire to use the proposed technique in the clinical arena is paramount. One such metric
is the North American Symptomatic Carotid Endarterectomy Trial (NASCET). This is a
confirmed clinical test that may benefit patients with high-grade carotid stenosis [14]. The
NASCET percent stenosis criterion is measured as: the diameter of lumen at the point of
maximal stenosis, subtracted from the diameter of the lumen of the normal internal carotid
artery, divided by the normal internal carotid artery multiplied by 100% [14]. The diameter
of maximal stenosis is most often found just above the carotid bulb, near the bifurcation of
the internal and external carotid arteries. A visual representation of this is shown in 4(a). This
test is generally performed by catheter angiography – an invasive technique requiring
surgery. In this paper, we propose an alternative method of measurement from a transverse
segmented US image.
While, angiography will give a 2D representation on a longitudinal view of any given artery,
yet it will not reveal any information on the depth of that artery. Depth can be measured by
taking a cross-sectional area (transverse) slice of the carotid, as shown in Figure 2-3(b). This
additional information should improve the traditional NASCET measurements. However,
slight modification to our measurements is needed in order to conform to the NASCET
standard. Since NASCET percent stenosis is based on artery diameters, where the proposed
measure is based on areas, (in a generally elliptic fashion) each contour would be square
rooted before the ratio is calculated. This will help to preserve the ratio of percent stenosis in
a range that traditional clinicians are already familiar with, rather than introducing an entirely
new range for stenosis.
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(a)

(b)

Figure 2-2: Active contour on a carotid ultrasound image. (a) without a-priori
knowledge. (b) with a-priori knowledge.
ICA
B

L

A

ECA

CCA

NASCET:

BA
 100%
B
(a)

(b)

Figure 2-3: (a) Drawing of NASCET criteria for evaluation of carotid stenosis: A is the
diameter of the residual lumen at the point of maximal stenosis (vertical lines
representing plaque); B is the diameter of the normal artery distal to the stenosis.
(CCA, ECA and ICA stand for Common, External and Internal Carotid Artery,
respectively) (b) Ultrasound image of a cross-sectional slice, at line L in (a), showing the
area of the carotid. Image is histogram equalized for better visualization.
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2.3 Results
In this study, 91 carotid artery US images are used. These images include normal and
diseased carotid arteries at different positions along the carotid artery, e.g., common carotid,
carotid bulb, and internal carotid. Manual carotid lumen segmentation was performed on all
of the images by a clinical radiologist. The images were then segmented by the proposed
snake algorithm. These images were acquired using a SONOS 5500 by Philips Medical
System.
Figure 2-4(a) shows a transverse 2-dimensional US image of the carotid bulb. Figure 2-4(b)
represents the manually segmented region of the carotid bulb by a clinical radiologist at the
given A position designated by the NASCET measure (as shown in Figure 2-3(a)). Figure 24(c) shows an example set of the four initial points plotted by the radiologist as an input to
the active contour and the result of initial ellipse extraction. These points should be placed
anywhere on the carotid lumen edge. They are required in order to achieve an elliptical
approximation and the initial contour. Each point placed is automatically connected to its
closest neighbour by means of a direct line of equally distanced points. Figure 2-4(d) shows
the result of the active contour following convergence. Similarly, Figure 2-5(a), (b), (c) and
(d) show the same for an internal carotid artery image (at location B designated by the
NASCET measure). These results were ascertained by using the proposed active contour
with parameters σ, l, u, α, β , γ, and τ, as 2.0, 0.2, 0.6, 0.09, 0.01, 0.5 and 0.4, respectively (as
defined in Section 2.1).
All images processed by the proposed algorithm were examined and reviewed by a
radiologist in a double-blind study in order to insure the segmentations were accurate. Due to
the subjectivity in estimating the borders, the radiologist reported that the proposed technique
would accurately objectify the inconsistencies among clinical practitioners. This will serve to
improve the computation of percent stenosis and other measures used in the clinical arena.
Overall, accuracy of the proposed system was measured by comparing the 91 cases to the
expert manual segmentations by the radiologist. These measurements include both type I and
type II errors as defined in [18]. Since the images at hand were mainly small segmented
foregrounds against vast backgrounds, the system would best be measured by means of its
sensitivity and precision rate. Sensitivity is the number of true positives divided by the
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number of true positives plus false negatives. In other words, it classifies how well a binary
classification test correctly identifies a condition. Precision rate is the number of true
positives divided by the number of true positives plus false positives. In other words, it
classifies how accurate the results of the test are versus its inaccuracies. Sensitivity of the
system, given a 95% confidence interval, yields 0.871 – 0.916. Whereas, precision rate, given
the same confidence interval, yields 0.866 – 0.903. It is worth mentioning that these reported
performance measures are quite high. This can be attributed to the fact that the initial points
to the proposed system were plotted by the specialist.

(a)

(b)

(c)

(d)

Figure 2-4: Transverse carotid artery US images of the carotid bulb. (a) the original
image. (b) the original image manually segmented by a clinical radiologist. (c) original
image with four points – white circles – placed by the clinical radiologist as an initial
value for the algorithm and the extracted prior ellipse as a dashed line. (d) the resulting
segmentation by the proposed active contour algorithm.
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(a)

(b)

(c)

(d)

Fig. 5. Transverse carotid artery US images of the internal carotid artery. (a) the original image.
(b) the original image manually segmented by a clinical radiologist. (c) original image with
points – white
circles –artery
placed US
by the
clinical of
radiologist
as an initial
valueartery.
for the (a)
Figure 2-5:four
Transverse
carotid
images
the internal
carotid
algorithm and the extracted prior ellipse as a dashed line. (d) the resulting segmentation by the
proposed
algorithm.
original image
(b)active
the contour
original
image manually segmented by a clinical radiologist.

the
(c)

original image with four points – white circles – placed by the clinical radiologist as an
initial value for the algorithm and the extracted prior ellipse as a dashed line. (d) the
resulting segmentation by the proposed active contour algorithm.

2.4 Conclusions
In this paper, a modified DP snake algorithm helped alleviate the inherent difficulties in
segmenting ultrasound carotid artery images, such as avoiding speckle noise and contour
bleeding. The proposed alterations utilized a modified Canny edge detector and a-priori
knowledge. Experimental results show that these alterations tune the original DP snake
model in order to be used in the medical arena so that clinical analysis results can be
improved.
A radiologist verified that this objective segmentation scheme would improve the calculation
of different clinical measures, such as percent stenosis, by reducing the inconsistencies and
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variability between clinicians while reducing the time for clinician interaction. We have
shown that the segmentation of the carotid artery is robust enough to be used in a clinical
setting for specific domain applications.
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Chapter 3 – Article 2
3 Active Contours with Optical Flow and Primitive Shape Priors
for Echocardiographic Imagery*
Abstract: Accurate delineation of object borders is highly desirable in echocardiography.
Among other model-based techniques, active contours (or snakes) provide a unique and
powerful approach to image analysis. In this work, we propose the use of a new external
energy for a GVF snake, consisting of the optical flow data of moving heart structures (i.e.
the perceived movement). This new external energy provides more information to the active
contour model to combat noise in moving sequences. An automated primitive shape prior
mechanism is also introduced, which further improves the results when dealing with
especially noisy echocardiographic image cines. Results were compared with that of expert
manual segmentations yielding promising sensitivities and system accuracies.
Keywords: Active contours, deformable models, snakes, gradient vector flow, shape priors,
optical flow, echocardiography.

3.1 Introduction
Echocardiography, imaging the heart using ultrasound waves, has become the most widely
used modality to observe heart motion and deformation over other modalities (e.g. Positron
Emission computed Tomography, Cardiac Magnetic Resonance, Computer Tomography).
This is due to the relatively inexpensive cost of the technology along with its non-invasive
nature, yielding no known side-effects. Sophisticated enhancements to the acquisition
devices over the years have yielded real-time dynamic observation of heart function.
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Unfortunately, US data still suffers from speckle noise. It may also exhibit occluded borders
due to the erratic scattering of its impinging waves (once it encounters various tissue
densities). Efforts have been made to compensate for these shortcomings, including filtering
[16] and incorporating the speckle noise effect directly into the algorithm [22]. Regardless,
boundary detection techniques need to be employed in order to segment a region of interest
(ROI). Analysis of these segmented regions has led to various works on endocardial borders
[5], stress and strain of the septum [17], and wall motility [1], which all help to accurately
diagnose cardiomyopathies.
Many computer vision techniques have been introduced in order to accomplish boundary
detection. One such example is the active contour model, also commonly known as snakes
[13].
Active contours treat the surface of an object as an elastic sheet that stretches and deforms
when external and internal forces are applied to it. These models are physically-based, since
their behavior is designed to mimic the physical laws that govern real-world objects [6].
Since this approach relied on variational calculus to find a solution, time complexity was a
major drawback. Amini et al. [2] and Williams and Shah [23] proposed algorithms that
reduced time complexity making the active contour model feasible for segmentation systems.
Issues with large capture ranges (the failure of curve migration when initialized distant from
the ROI to segment) and concavities (high internal energies may inhibit the capture of
smaller features) are solved by other advances, which include inflation forces [7],
probabilistic models [15], oriented particles [21], and gradient vector flows (GVF) [24]. For
the purposes of this study, focus will be placed on those advances best suited for
echocardiographic images.
Since the left ventricle represents one of the most important heart functions, many semiautomatic techniques have attempted to segment this region from its surrounding tissue.
Papademetris et al. [19] proposed to measure the stress and strain of cardiac regional
deformation of the left ventricle in ultrasound images by using a Markov random field [14].
Texture data was incorporated into their model for use with a tracking algorithm. However,
assumptions of uncorrelated data within their model are made (which may lead to a
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misclassification of structures due to noise) and complex calculations result in long
computation times.
Eusemann el al. [8] proposed the use of a modality independent quantitative visualization of
the peak velocities. Though set manually, the technique utilizes a set of polygon meshes to
deform by means of the anatomical centerline of the left ventricle.
Jolly [12] proposed a semi-automatic segmentation algorithm with the use of three manually
placed landmarks in order to estimate the location of various shape models. However, this
system was designed for use on the end-systole and end-diastole images only, rather than the
entire cardiac cycle.
Felix-Gonzalez and Valdes-Cristerna [9] proposed a technique using a series of standard
algorithms (e.g. mean shift filtering, edge mapping, entropy extraction and confidence
mapping) along with an active surface model in order to deal with the speckle. This model is
made up of cubic splines and is based on gradient descent, however no explanation is given
on parameterization and how the empirical data was set.
Zhou el al. [25] proposed the segmentation of MRI cardiac sequences using a generalized
fuzzy GVF map along with a relative optical flow field. Optical flow measurements are
computed on the cardiac sequence and a maximum a posteriori probability (MAP) is used as
a window for the movement of the curve. The use of optical flow with GVF provides
promising results, however since this technique is used exclusively on MRI data, there is no
guarantee that it would work with US data given the presence of speckle noise.
In practice, many of the stated segmentation algorithms can be used on normal
echocardiographic data. This is true given an adequate amount of user intervention and when
such data exhibits low levels of speckle noise (i.e. from newer machines generally found in a
research environment under ideal conditions with healthy volunteers). However in a clinical
setting, the objective is to be able to accurately identify myocardial borders on problematic
echocardiograms with minimal time.
In this paper, we will present an external energy for GVF snakes that takes advantage of the
motion data within echocardiographic image cines. Furthermore, we incorporate the use of
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primitive shape priors such that the contour placement will improve, especially when dealing
with noisy regions and improper initialization.
The rest of the paper is organized as follows. Background information on relevant models
will be briefly described in Section 2. The proposed scheme will be outlined in Section 3.
Section 4 and Section 5 will contain the experimental results and conclusions, respectively.

3.2 Background
3.2.1 Active Contours
A snake is an energy minimization problem. Its energy is represented by two forces (internal
energy, Ein, and external energy, Eex) which work against (or independent of) each other. The
total energy should converge to a local minimum; ideally at the desired boundary. A snake
can be parametrically defined as v(s) = [x(s), y(s)]T, where s belongs to the interval [0,1].
Hence, the total energy to be minimized, EAC, to give the best fit between a snake and a
desired object shape is:
1

E AC   Ein (v( s ))  Eex (v( s )) ds

(1)

0

where Ein decreases as the curve becomes smooth and Eex decreases as it approaches the ROI,
such as image structures or edges (i.e. areas of high gradient information).
As in [13] the internal energy of the active contour formulation is further defined as:
2

Ein (v( s ))   ( s ) 

dv
d 2v
  (s)  2
ds
ds

2

(2)

where α(s) and β(s) are weighting factors of elasticity and stiffness, respectively. The first
order term encourages the snake’s surface to act like a membrane, whereas the second order
term encourages the snake to act like a thin plate. α(s) controls the tension along the spine
(stretching a balloon or elastic band) whereas β(s) controls the rigidity of the spine (bending
a thin plate or wire).
A typical external energy formulation for a given image, I(x,y), to identify edges is:
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Eex ( x, y )   I ( x, y )

2

(3)

where  denotes the gradient operator. In the case of a noisier image the edges are further
smoothed:
Eex ( x, y )   G ( x, y )  I ( x, y )

2

(4)

where Gσ(x,y) is a two-dimensional Gaussian function with standard deviation σ, and 
denotes a convolution operator. σ must be large enough to compensate for the image noise
that would interfere with the active contour’s capture range (the contour may get trapped by
the noisy areas of the image).
The standard snake algorithm suffers from poor range due to initialization and the inability to
capture concavities. Xu and Prince [24] largely solved this problem by the advent of the GVF
snake, which provides a field for guiding the contour to regions of high gradient. The GVF
field is used as an external energy and is characterized by the vector field
z(x,y)=[u(x,y),v(x,y)] that minimizes the energy functional:
EGVF     (| u |2  | v |2 ) dxdy
  | f |2  | z  f |2 dxdy

(5)

where f = −Eex is an edge map derived from the image and μ is the degree of smoothness of
the field. Figure 3-1 shows an example of a GVF field on a standard U-Image.

Figure 3-1: An example of the virtual electric field on standard U-Image.

3.2.2 Optical Flow
Optical flow approximates the apparent motion of an object over a series of images (or time).
The relationship between the optical flow in the image plane and the velocities of objects in
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the three-dimensional world is not necessarily obvious [3]. For the sake of convenience, most
optical flow techniques consider a particularly simple world where the apparent velocity of
brightness patterns can be directly identified with the movement of surfaces in the scene.
This implies that objects maintaining structure with changing intensity would break this
assumption.
Consider an image intensity, I(x,y,t) at time t. Time, in this instance, implies that next frame
in an image cine. Assuming that at a small distance away, and some time later the given
intensity is:
I ( x  x, y  y, t  t )  I ( x, y, t )


(6)

I
I
I
x  y  t  higher order terms
x
y
t

Given that the object started at position (x,y) at time t, and that it moved by a small distance
of (∆x, ∆y) over a period of ∆t, the following assumption can be made:
I ( x  x, y  y, t  t )  I ( x, y, t )

(7)

The assumption in (7) would only be true if the intensity of our object is the same at both
time t and t + ∆t. Furthermore, if our ∆x, ∆y and ∆t are very small, our higher order terms
would vanish:
I
I
I
x  y  t  0
x
y
t

(8)

Hence dividing (8) by ∆t will yield:


I I x I y


t x t y t

(9)

I
I
u v,
x
y

(10)

 It 

where u  x and v  y .
t

t
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The equation in (10) is known as the optical flow constraint equation, where It at a particular
pixel location, (x,y), is how fast its intensity is changing with respect to time, u and v are the
spatial rates of change for any given pixel (i.e. how fast an intensity is moving across an
image). However, effectively estimating the component of the flow (along with intensity
values) cannot directly be solved in this form since it will yield one equation per pixel for
every two unknowns, u and v. In order to do so, additional constraints must be applied to this
equation.
Horn and Schunck [11] introduced a method for solving this problem using partial
derivatives. A global regularization constraint is used which assumes that images consist of
objects undergoing rigid motion, and so over relatively large areas the optical flow will be
smooth. Figure 3-2 depicts a visual representation of the optical flow of a simple Rubik’s
cube. Note that the grayscale image has few shadows. This helps to maintain consistency in
the luminance of each pixel which in turn yields accurate results.

(a)

(b)

(c)

Figure 3-2: An example of an optical flow field on a Rubik’s cube rotated image; (a)
Rubik’s cube at time t; (b) Rubik’s cube at time t+∆t; (c) optical flow.

3.3 Description of Proposed Model
The use of the GVF snake directly on echocardiograms will not provide an adequate solution
due to the complication of noise and other valves that exist within the heart cavity. Hence our
scheme will make use of a GVF snake with optical flow measurements. These measurements
will be included in EGVF.
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By considering each image cine within an echocardiographic video loop, the Horn-Schunck
technique [11] is applied in order to detect the motion between various heart structures.
These optical flow measurements will further filter noise from the cines since speckle tends
to be stable throughout an image. As such, noise will be assigned smaller magnitudes of
movement over surrounding structures and hence will be eliminated.
The magnitude of these optical flow estimates are then median filtered and the canny edge
map [4] is extracted in order to generate the GVF field for the snake’s external energy.
Since the generation of the GVF field is computationally prohibitive using real world data,
the external energy is generated using a virtual electric field (VEF) of the preprocessed edge
map [20]. The VEF is defined by considering each edge as a point charge within an electric
field. This can be accomplished by convolving the edge map with the following two masks:
g x ( x, y ) 

x
4  ( x 2  y 2 ) 3 / 2

(11)

g y ( x, y ) 

y
4  ( x 2  y 2 ) 3 / 2

(12)

where  is sufficiently small. Given a sufficient mask size, the resulting field yields a vector
flow identical to the GVF field defined in (5), without the high computational cost. For
instance, the vector field shown in Figure 3-1 was generated with (11) and (12) with a mask
size of 32.
Since many of the anatomical structures (such as the left ventricle of the heart) are known
shapes and sizes, prior knowledge information can be directly used to increase the
performance of a segmentation algorithm.
Priors based on shape statistical models require modifications to the standard active contour
model. An iterative solution can be directly incorporated into any optimization model by
using the proposed framework first outlined by [10].
Since it is desirable to incorporate shape priors into the model without directly involving the
user,
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2/3 upper region
Snake of
LV
1/3 lower region

Shift in order
to attain
optimal prior

Figure 3-3: Generation of primitive priors on active contour points.

Figure 3-4: An example of a primitive prior formulation on the left ventricle.
automated shape detection takes place on the set of discrete snake points, v(s). This is
achieved by replacing Eex of our active contour with a least squares fit polynomial
(specifically a third order hyperbola) of the current v(s) points. This allows the fitting of a
primitive shape (or a series of primitives as needed for the left ventricle) to the curve set v(s).
This will help compensate for the noise that inhibits the snake from migrating past a certain
point. The user is able to increase or decrease the effect of the prior knowledge to the snake’s
convergence cycle.
Depending on the feature of interest to be segmented, different primitive priors can be used
in order to improve the robustness of the technique. The priors are not limited to hyperbolas;
rather a range of shapes can be selected by the user in order to best fit their feature of interest.
This is useful in the medical arena where a specialist has a clear understanding of the
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underlying structure being detected, such as a liver, an artery, or a heart. A desired primitive
shape can be selected before curve evolution takes place.
Figure 3-3 portrays the means of generating a primitive prior for the left ventricle of the 4
chamber view US heart image. The left ventricle points were split into an upper region and a
lower region representing two separate shape fitting equations. This can be tuned to give the
best prior by selecting the separation line of the regions with the least amount of distance
between the fitted hyperbolas and snake curve. Further advantages are that the prior
knowledge is not built on a set of training samples that are expert delineated; rather they are
generated from the current active contour control points. Figure 3-4 shows the results of the
prior generation scheme on a echocardiogram.
Once the prior is constructed, a VEF is generated of the prior and a single optimization
iteration of the snake is executed before returning to the original optimization cycle. This is
referred to as an omega iteration. This interruption to the snake optimization cycle is repeated
throughout the snake’s evolution, until it achieves equilibrium. A flow chart of the proposed
scheme is shown in Figure 3-5.

3.4 Experimental Results
For this study, a series of B-mode echocardiogram cross sectional videos of the heart have
been used to investigate the proposed snake algorithm. These videos were acquired using a
SONOS 5500 by Philips Medical System. The transducer frequency was set at 2.5 Mhz in
order to insure adequate penetration of tissue, while maintaining image quality with the
existing speckle noise. Longitudinal views of the heart, which visualize the left ventricle,
were acquired in order to verify the prior knowledge algorithm using more than one primitive
shape.
The videos were parsed into image cines and each frame was considered with its direct
neighbouring frame. Optical flow calculations for the edge map were completed using the
Horn-Schunck technique with a regularization constraint of 0.05 in order to compensate for
the general speckle throughout the US images. Mask size for VEF generation was set to 64
and was normalized for active contour use. The initial contour placement was set to a circle
of radius 30, which was placed by the user within the left ventricle of the heart.
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Figure 3-5: Flow Chart of Proposed Algorithm

(a)

(b)

(c)

Figure 3-6: Segmenting the left ventricle of the heart (a) Expert manual segmentation
(b) standard GVF segmentation (c) GVF-optical flow segmentation with priors.
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Snake parameters,  and , were set to 4 and 0, respectively.  was set to 4 in order to add a
substantial amount of weight to the internal energy.  was set to 0 since the second order
differential does not influence the snake enough to warrant the added time complexity. Priors
(omega iteration) were invoked every five iterations of the snake minimization.
Figure 3-6(a) shows an expert manual segmentation of the left ventricle of the heart. Figure
3-6(b) shows the final contour using the traditional GVF snake. Figure 3-6(c) shows the final
contour using the optical flow GVF snake with primitive priors. Expert examination of the
results reveals that the shape priors improve regularity by allowing the snake to overcome
noise, artifacts. This allows for proper delineation of the left ventricular endocardial lining.
The optical flow measurements provide the necessary structural information used in the
external energy of the snake.
Experiments were run on a complete cardiac cycle with various external energies. The first
consisting purely of the optical flow measurements, the second on a combined energy of
image gradient vectors and optical flow data.
Overall, accuracy of the proposed system was measured by comparing the 87 indexed images
to the expert manual drawn segmentations by a clinician on the actual endocardial borders.
These measurements include both type I and type II errors as defined by [18]. Since the
images were mainly small segmented foregrounds against vast backgrounds, the system
would best be measured by means of its sensitivity and system accuracy.
Sensitivity is the number of true positives divided by the number of true positives plus false
negatives. System accuracy is the number of true positives and true negatives divided by the
total number of pixels in the image. In other words, it classifies how accurate the results of
the test are versus the total image.
The sensitivity of the system, given a 95% confidence interval, yields 0.568-0.610 when
using the optical flow exclusively. However, this yield increased to 0.722-0.759 when
combined with an image gradient vectors. Whereas, system accuracy, given the same
confidence interval, yields 0.940-0.946 for the optical flow energy and 0.954-0.958 for the
combined energy, respectively.
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Figure 3-7: Sensitivity using different external energies

Figure 3-8: System Accuracy using different external energies.
Figure 3-7 shows the sensitivity of the system using various energies. Figure 3-8 shows the
system accuracy of the system. We notice that there is a slight improvement when
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segmenting using both the optical flow and the image gradient over the optical flow
exclusively. This illustrates that the optical flow measurements contribute enough
information to the snake in order to segment out the left ventricle.

3.5 Conclusions
In this paper, we have shown that the use of optical flow calculations can be used as an
external energy within the GVF active contour framework. By exclusively using the optical
flow calculations, we have shown that it is possible that an active contour method can make
use of the knowledge derived from the apparent motion of tissue. This strengthens the
principle that the movement of tissue masses should be considered within segmentation
techniques, where the data facilitates it.
Furthermore, contour regularity and accuracy was improved by using primitive shapes priors.
The inherent difficulties in segmenting echo-cardiographic images, such as avoiding speckle
noise and valve interference were also overcome by the primitive priors. Results were
validated against a gold standard which was manually segmented by a clinician.
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Chapter 4 – Article 3
4 SRAD, Optical Flow and Primitive Prior based Active
Contours for Echocardiography*
Abstract: Accurate delineation of object borders is a highly desirable in echocardiography,
especially the left ventricle. Among other model-based techniques, active contours (or
snakes) provide a unique and powerful approach to image analysis. In this work, we propose
the use of a novel external energy for a gradient vector flow (GVF) snake. This energy
consists of optical flow estimates of heart sequences along with the use of a speckle reducing
anisotropic diffusion (SRAD) operator. This energy provides more information to the active
contour model garnering adequate results for noisy moving sequences. Furthermore, an
automatic primitive shape prior algorithm was employed to further improve the results and
regularity of the snake, when dealing with especially speckle laden echocardiographic
images. Results were compared with expert-defined segmentations yielding better sensitivity,
precision rate and overlap ratio than the standard GVF model.
Keywords: Image segmentation, active contours, gradient vector flow, optical flow, shape
priors, curve fitting, echocardiography.

4.1 Introduction
The assessment of cardiac function has been a major area of interest in the medical field.
Normal heart function consists of pumping chambers (known as ventricles) which regulate
the systemic and pulmonary circulation systems by delivering blood to the proper areas.
Detection of non-normal heart function in the left ventricle (LV), for instance, can cause
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systolic dysfunction, being the reduction in the ability to contract, or diastolic dysfunction,
being the inability to fill efficiently. Various heart structures may also fail causing
cardiomyopathies, endangering the life of the host individual. Fortunately, many myopathies
are treatable (with medication, implanted pacemakers, defibrillators, or ventricular assist
devices) given early detection. Echocardiography, imaging the heart using ultrasound waves,
facilitates the ability to do so.
The advent of real time ultrasonography provides the ability to image an entire LV and
surrounding anatomy within one cardiac cycle (approximately one second). However,
depending on the patient’s ‘photogenicity’ (impacting factors include surrounding fatty
tissues, calcifications, gender), these images are most likely marred by speckle artifacts.
Many computer vision techniques attempt to reduce such speckle noise by means of filtering
[16] or incorporating the speckle effect directly into their algorithms [22]. Normally, these
ultrasound images are analyzed for area and volume assessment by trapezoidal estimation.
Such techniques introduce a large user bias into the calculations and are quite time
consuming on the clinicians behalf. The advent of boundary detection techniques can help to
automate this task. Boundary detection techniques are employed in order to segment the
wanted regions for analyses on the heart structures, such as endocardial borders [5], stress
and strain of the septum wall [17], and wall motility [1] to name a few.
Kass el al. [12] first proposed the original active contour model (commonly known as a
snake or a deformable model). In their formulation, image segmentation was posed as an
energy minimization problem.
Active contours treat the surface of an object as an elastic sheet that stretches and deforms
when external and internal forces are applied to it. These models are physically-based, since
their behaviour is designed to mimic the physical laws that govern real-world objects [6].
Since this approach relied on variational calculus to find a solution, time complexity was one
of the main drawbacks of this original model. Amini et al. [2] proposed an algorithm for
using dynamic programming, in order to incorporate soft and hard constraints into the
formulation, improving time complexity and results. Further improvements to time
complexity were proposed by Williams et al. [23], by using a greedy algorithm while
incorporating a simple curvature approximation. Issues with large capture ranges and
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concavities are solved by other advances, which include inflation forces [7], probabilistic
models [15], oriented particles [21], and gradient vector flows [24]. For the purposes of this
study, focus will be placed on those advances best suited for echocardiographic images.
Since the LV represents one of the most important heart functions, many semi-automatic
techniques attempt to segment this region from surrounding tissues [5][7][18]. Yet, no
universally accepted standard exists for segmenting echocardiographic images.
Papademetris et al. [18] took advantage of a b-splines parameterized deformable model for
segmenting cardiac regions. The external energy consisted of the standard intensity term and
a texture-based markov random field (MRF) term. The MRF is based on a combination of
gradient, regional and curvature data computed from the original image. Initial contours are
manually placed for each 2D plane and are passed to a shape tracking algorithm.
Displacements are probabilistically computed using a confidence measurement for the entire
set. Final displacements are fed into an anisotropic linear elastic model which is computed
vis-à-vis a Bayesian estimation framework. The manual placement of the contours makes this
technique quite labour intensive.
Felix-Gonzalez et al. [7] proposed a segmentation technique for echocardiographic images
using an active surface model (ASM). The ASM is made up of cubic splines and is based on
a gradient descent procedure. When using gradient descent, the empirical setting of
parameters is required based on the quality and types of images used. This makes this
proposed technique extremely sensitive to its input. Furthermore, Felix-Gonzalez et al.’s
work was only tested on two limited datasets.
Leung et al. [13] proposed the use of an active appearance model (AAM) and intensity based
registration for segmenting multiple 2D image slices. An AAM uses all the information in an
image region covered by the target object, rather than just that near modeled edges. An AAM
involves the principal component analysis of the various shapes and textures from several
manually segmented 2D slices for training. The AAM makes use of the training set to
converge the initial set mesh to the best textures on the image. However, this trained set
required several manual segmentations of the 2D image slices to tune it to the medium being
used.
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The gradient vector flow (GVF) [24] snake was introduced as a modification to the original
snake model in order to overcome the capture range and curve concavity issues. However,
using the GVF snake directly on echocardiograms will not provide an adequate solution due
to the complication of speckle noise and the existence of valves within the heart cavity,
inhibiting a proper segmentation.
Zhou et al. [25] proposed the segmentation of MRI cardiac sequences using a generalized
fuzzy gradient vector flow (FGVF) map along with a relative optical flow field. Optical flow
measurements are computed on the cardiac sequence being considered and a maximum a
posteriori probability (MAP) was used as a window for the movement of the curve. The use
of optical flow with GVF provides promising results, however this technique is used
exclusively on clear MRI data, and hence the presence of speckle noise on echocardiographic
images would require modifications of this technique. Both GVF and optical flow
measurements will be used in the proposed technique.
The proposed segmentation algorithm differs from previous works mainly in that it combines
the benefits of multiple data sources within echocardiographic video cines. This includes the
collection of motion data (helping to solve the static noise problem), localized detail data
(helping to solve the inherent speckle noise problem), and structural data (helping to solve
the occluded borders problem), which are represented by the optical flow module, the speckle
reducing anisotropic diffusion (SRAD) edge map and the primitive priori knowledge module
respectively.
The rest of this paper is organized as follows. In Section 4.2, the proposed scheme will be
introduced. Results and discussion will be presented in Section 4.3, and Section 4.4 will
contain conclusions.

4.2 System and Methods
In this study, we utilize and improve our previous preliminary works [8][9][10]. The
proposed scheme will contain a fusion of knowledge about the image in order to improve the
automation and inter-variable efficiency of left ventricular segmentation methods. The
system will incorporate three distinct elements into the external energy of the active contour.
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These elements are SRAD measurements, optical flow estimates and priori knowledge
measurements on contour points.

4.2.1 Parametric Active Contour Review
A snake is an energy minimization problem. Its energy is represented by two forces (internal
energy, Ein, and external energy, Eex) which work against each other. The total energy should
converge to a local minimum – in the perfect case – at the desired boundary. The snake is
defined as v(s) = [x(s), y(s)]T, where s belongs to the interval [0,1]. Hence, the total energy to
be minimized, EAC, to give the best fit between a snake and a desired object shape is:
E AC   Ein v( s )   Eex v( s )  ds
1

(1)

0

The internal energy decreases as the curve becomes smooth (by incorporating both elasticity
and stiffness); whereas the external energy decreases as approaching the features of interest,
such as image structures or edges.
The internal energy of the active contour formulation is further defined as:
Ein v( s )    ( s )

2

dv( s )
d 2 v( s )
  ( s)
ds
ds 2

2

(2)

where α(s) and β(s) are weighting factors of elasticity and stiffness terms, respectively. The
first order term makes the snake’s surface act like a membrane. The weight α(s) controls the
tension along the spine (stretching a balloon or elastic band). The second order term makes
the snake act like a thin plate. The weight β(s) controls the rigidity of the spine (bending a
thin plate or wire).
A typical external energy formulation to identify edges for a given image, I(x,y), is:
E ex ( x, y )   I ( x, y )

2

(3)

where  denotes the gradient operator. In the case of a noisier image the edges are further
smoothed:
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Eex ( x, y )   G ( x, y )  I ( x, y ) 

2

(4)

where Gσ(x,y) is a two-dimensional Gaussian function with standard deviation σ, and 
denotes a convolution operator. Since the contour may get trapped by the noisy areas of the
image, σ must be large enough to compensate for the image noise that would interfere with
the active contour’s capture range. The standard snake algorithm also suffers from poor
capture range due to initialization and the inability to capture concavities. These problems are
largely solved by the advent of the GVF snake [24].
The concavity problem exists since the gradient vectors in an image generally have large
magnitudes only in the immediate vicinity of the boundary, and are nearly zero at points
further away from the boundary. As such, the capture range of the snake will be quite small.
In order to resolve this, the gradient map is extended to points away from boundaries using a
computational diffusion process. The GVF field is used as an external energy in the active
contour and is characterized by the vector field z(x,y)=[u(x,y),v(x,y)]T that minimizes the
energy functional [24]:
E GVF    (| u | 2  | v | 2 )  | f | 2 | z  f | 2 dxdy

(5)

where f is an edge map derived from the image, μ is the degree of smoothness of the field, u
and v characterize the direction and strength of the field. Hence, when

| f |

is small the

energy will be dominated by the partial derivates, yielding a slow field. Alternatively, when
| f |

is large, the latter term dominates and the function is minimized by setting z  f .

The external energy for the proposed scheme will be generated using a virtual electric field
(VEF) [20] of f over the traditional GVF technique. Traditional GVF field generation is
performed by optimizing the cost function represented as the different partials shown in (5),
which is quite a time consuming process. The VEF is defined by considering each edge pixel
as a point charge within an electric field. This can be accomplished by convolving the edge
map with the following two masks:
g x ( x, y ) 

cx
(x 2  y 2 )3 / 2

(6)
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c y
(x  y 2 )3/ 2

g y ( x, y ) 

2

(7)

where c = (4πε)-1 and  is sufficiently small constant. The resulting field yields a vector flow
identical to a GVF field; given the masks are of sufficient size. A smaller mask size would
ignore outlying edges that would have little impact on the interested features since their range
is quite far. However, since echoardiographic images contain many features throughout the
image, quantizing any part of the edge map is not an option.
According to Park et al. [19], an area of radius 32 around the feature should provide
adequate flow vectors to accurately recreate a GVF field, without suffering from the high
computational cost associated with vector flow generation. Figure 4-1(b) shows an example
of a vector flow field on the standard U-Image, shown in Figure 4-1(a), using 65 × 65 masks
generated from (6) and (7), which is identical to the original GVF field.

4.2.2 SRAD Measurements
Diffusion is a process that equalizes differing concentrations without creating or destroying
an object’s mass. Simple diffusion can be defined as
p t
 div D  p t
t





(8)

where div is the divergence operator, D is the diffusivity tensor, and p refers to the diffused
image at time point t. In Perona and Malik’s anisotropic diffusion model [20], they defined
D for smoothing image data as



D  g p t



(9)

1
 p
1 
 


t






2

where λ is the edge magnitude parameter. Hence, g(.) will yield low values (near zero) for
gradient values much greater than λ inhibiting diffusion near edges. Using (9) as the
diffusivity coefficient of (8), the model sharpens edges if their gradient value is larger than
the edge magnitude parameter λ by inhibiting diffusion. In other words, g(.) acts as a means
to standardize edge response across homogeneous regions and non-homogeneous regions.
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(a)

(b)

Figure 4-1: Example of gradient vector forces; (a) standard U-Image, and (b) Gradient
Vector Flow of U-Image
Yu et al. [25] introduced the instantaneous coefficient of variation (ICOV) as a noiseestimating operator. The ICOV operator is defined by



2

 

ICOV p 

1 / 2  p t 1 / 16   2 p t

t



2

(10)

 p 1 / 4   p 
t

2

t

where 2 is the Laplacian operator. By combining the anisotropic diffusion model with the
ICOV operator, Yu et al. [25] yielded a partial differential equation called the speckle
reducing anisotropic diffusion (SRAD).

 

SRAD p t  p t  t  p t 

t
 div g ICOV p t  p t
| |



 



(11)

where, |η| is the number of pixels in the neighbourhood of pixel x (usually taken to be equal
four). Yu et al. [26] showed that using (11) provided better results at detecting real borders
when faced with high levels of speckle noise.
Applying SRAD on the echocardiograms will help to reduce much of the speckle that
impedes the accurate calculation of optical flow, which will be incorporated into the external
energy. SRAD edge-maps will also be fed as the gradient estimates for the snake.
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4.2.3 Optical Flow Estimates
Optical flow approximates the apparent motion of an object over a series of images (or time).
The relationship between the optical flow in the image plane and the velocities of objects in
the three-dimensional world is not necessarily obvious [3]. For the sake of convenience, most
optical flow techniques consider a particularly simple world where the apparent velocity of
brightness patterns can be directly identified with the movement of surfaces in the scene.
This implies that objects maintaining structure but changing intensity would break this
assumption.
Consider an image intensity, I(x,y,t) at time t. Time, in this instance, implies that next frame
in an image cine. Assuming that at a small distance away, and some time later the given
intensity is:
I ( x  x, y  y, t  t )  I ( x, y, t ) 

I
I
I
x  y  t  higher order terms
x
y
t

(12)

Given that the object started at position (x,y) at time t, and that it moved by a small distance
of (∆x, ∆y) over a period of time ∆t, the following assumption can be made:
I ( x  x, y  y, t  t )  I ( x, y, t )

(13)

The assumption in (13) would only be true if the intensity of our object is the same at time t
and t + ∆t. Furthermore, if our ∆x, ∆y and ∆t are very small, our higher order terms would
vanish, i.e.,
I
I
I
x 
y  t  0
x
y
t

(14)

Dividing (14) by ∆t will yield:


 It 

I I x I y


t x t y t

(15)

x and
y .
I
I
u  v , where u 
v
t
x
y
t

(16)
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Equation (16) is known as the optical flow constraint equation, where It at a particular pixel
location, (x,y), is how fast its intensity at this location is changing with respect to time, u and
v are the spatial rates of change for any given pixel (i.e., how fast an intensity is moving
across an image). However, effectively estimating the component of the flow (along with
intensity values) cannot directly be solved in this form since it will yield one equation per
pixel for every two unknowns, u and v. In order to do so, additional constraints must be
applied to this equation.
Lucas-Kanade [14] and Horn-Schunck [11] introduced two common methods for solving this
problem using partial derivatives. The former assumes that the flow field is locally smooth
(for a given static window size) and then solves (16) by means of a least squares
approximation technique. The latter uses a global regularization parameter which assumes
that images consist of objects undergoing rigid motion, resulting in a smooth optical flow
over a relatively large area. Figure 4-2 depicts a visual representation of the optical flow of a
simple Rubik’s cube. Notice that the greyscale image has few shadows, helping to maintain
consistency in the luminance of each pixel, hence yielding accurate results.
When dealing with noisy echocardiograms, a global regularization parameter will deal with
the speckle better than the static window. This is due to the speckle noise remaining
relatively static, lacking fluidity, throughout an image. Hence, the speckle will be ‘filtered’,
since the optical flow calculations will fail to realize it within the frames.

(a)

(b)

(c)

Figure 4-2: An example of an optical flow field on a Rubik’s cube rotated image; (a)
cube at time t, (b) cube at time t+∆t, and (c) Optical flow of image (a) to (b) using LucasKanade method (originally published in Barron et al. [3]).
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Optical flow magnitudes will be combined with the SRAD edge maps (see Section 4.2.5), in
order to generate the external energy in (1) of the GVF snake. This will help to reduce
artifacts due to static speckle noise, while also providing more information for the contour
points to track (i.e., the movement of the tissue mass).

4.2.4 Primitive Shape Measurements on Contour Points
Since we are dealing with structures that have known shapes and sizes, and many real-world
models have been already measured, prior knowledge information can be directly used to
increase the performance of a segmentation algorithm. Priors based on shape statistical
models require modifications to the standard active contour model. An iterative solution can
be incorporated directly into any optimization model by using the proposed framework.
Since it is desirable to incorporate shape priors without directly involving the user for
training, automatic shape detection takes place on the set of discrete snake points, v(s). This
is achieved by first generating the least squares fit polynomial(s) of the current v(s) points.
For our left ventricle application, snake points were divided into an upper region and a lower
region representing two separate third-order hyperbolas, which will better suit the shape of
the left ventricle during both systole and diastole, though any shape prior can be represented
by means of simple primitives. Least squares fitting technique is utilized to estimate the two
hyperbolas coefficients. The axis separating the two regions is computed by taking the twothirds upper and one-third lower bounds on all snake points and computing their division.
This division can be tuned by shifting it upwards or downwards (either manually by the user
or automatically by the system) in order to minimize the distance between the fitted
hyperbolas and snake points.
Priors are then generated by joining the fitted primitives to form one solid shape. Primitives
are bounded by the furthest easterly and westerly points by the snake points, in order to
prevent the possibility of a non-connecting shape.
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2/3 upper region
Snake of
LV
1/3 lower region
Shift in order
to attain
optimal prior

upper hyperbola
lower hyperbola

(a)

(b)

Figure 4-3: Left ventricle primitive shape fitting; (a) primitive shape fitting algorithm
using two hyperbolas, and (b) echocardiogram with segmentation overlay; solid line
represents primitive whereas X-line represents active contour
Once priors have been generated, its GVF field is computed. This new field will replace the
existing external energy of the GVF snake for this specific snake iteration. Figure 4-3
portrays the process of generating a primitive prior for the left ventricle of the 4-chamber
view image, where two intersecting hyperbolas are used (default shape for our left ventricle
application).
The fitting of a primitive shape (or a series of primitives as needed for the left ventricle) to
the snake points, v(s), will help compensate for the noise that inhibits the snake from
migrating past a certain point. It will also help retract the snake towards the primitive prior
when an occluded border exists; common in many echocardiographic images. The user can
control the number of cycles between any two consecutive prior calculation cycles (prior step
parameter). This allows for the increase or decrease in the inherent effect of the prior
knowledge to the snake’s convergence cycle.
This primitive prior module is useful in the medical arena where the specialist or clinician
has a clear understanding of the underlying structure being detected, such as a liver, an
artery, or a heart. They can choose their desired primitive shape (or series of shapes) before
curve evolution takes place.
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4.2.5 Fusion Characteristics
The proposed external energy is a fusion of SRAD gradient edge-map information and the
optical flow estimates. Figure 4-4 illustrates a top-level block diagram of the proposed
system. It starts by calculating the SRAD edge map of the image cines (as explained in
Section 4.2.2). The edge maps optical flows are then extracted (as explained in Section
4.2.3). The estimated optical flow is median filtered and are added to the SRAD image edge
map following normalization. This result is used to generate the GVF for the snake’s external
energy. GVF snake evolution (as explained in Section 4.2.1) iterates to further minimize the
energy function until a prior cycle condition is satisfied (as explained in Section 4.2.4), at
which, the prior cycle is initiated. During the prior cycle, a GVF is generated from the
desired primitive and a single optimization evolution of the snake is executed before
returning to the original non-primitive snake iterations. This process is repeated until the
snake is optimized and equilibrium is achieved.

4.3 Results and Discussion
For this study, a series of B-mode echocardiogram cross-sectional videos of the heart have
been used to investigate the proposed snake algorithm. These videos were acquired using a
SONOS 5500 by Philips Medical System. The transducer frequency was set at 2.5 MHz in
order to insure adequate penetration of tissue, while maintaining image quality with the
existing speckle noise. Longitudinal views of the heart, which visualize the left ventricle,
were acquired in order to verify the prior knowledge algorithm using more than one primitive
shape.
The videos were parsed into image cines and each frame was considered with its direct
neighbouring frame. Optical flow calculations for the edge map were completed using the
Horn-Schunck technique with a regularization constraint of 0.2 in order to compensate for
the general speckle throughout the US images. The initial contour placement was set to a
small circle which was placed by the user within the left ventricle of the heart and the prior
step parameter was set to 5 cycles.
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Figure 4-4: Top level block diagram of proposed scheme
Overall, experiments were run on eight complete cardiac cycles from different patients. The
performance of the proposed system was measured by comparing 130 indexed segmented
image cines from the eight cardiac cycles to the manually delineated segmentations by an
expert radiologist, representing the gold standard used. Since the images at hand were mainly
small-segmented foregrounds (left ventricular surface area) against vast backgrounds, the
system performance would best be measured by means of its sensitivity, precision rate and
overlap ratio. Let us consider the following metrics; a true positive pixel is a pixel that is
considered part of the left ventricle by both of the proposed method and the gold standard. A
false positive pixel is a pixel that is considered part of the left ventricle by the proposed
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method but it is not considered as such on the gold standard. A false negative pixel is a pixel
that is not considered as part of the left ventricle by the proposed method, yet it is considered
to be part of the ventricle according to the gold standard. The sensitivity is the percentage of
the number of true positive pixels divided by the sum of the number of true positive pixels
and false negative pixels. In other words, it classifies how well a binary classification test
correctly identifies a condition.
Precision rate is the percentage of the number of true positive pixels divided by the sum of
the number of true positive pixels and false positive pixels. In other words, it classifies how
accurate the results of the test when the results are positive. Overlap ratio is the percentage of
the number of true positive pixels divided by the sum of the number of true positive pixels,
false positive pixels and false negative pixels.
The sensitivity, precision rate and overlap ratio of the proposed system on the 130 segmented
cines are shown in Table 4-1. This was generated by combining the total metric aggregates
across all 130 cines, and calculating the sensitivity, precision rate and overlap ratio measures.
Examination of Table 4-1 shows that the proposed technique outranks the standard GVF
snake in all of the metrics shown.
Table 4-1: Sensitivity, precision rate and overlap ratio of the proposed system
Sensitivity
Standard GVF Snake
GVF Snake with SRAD
Optical flow and priors

90.4%
92.9%

Precision
Rate
70.2%
77.4%

Overlap
Ratio
65.3%
73.0%

An example of segmentation results is exhibited in Figure 4-5, where Figure 4-5(b) reveals
the SRAD contours used in the external energy of the proposed scheme, Figure 4-5(c) shows
the expert manually traced delineation of the left ventricle, (d) shows the segmentation
results when utilizing GVF only, and Figure 4-5(e) reveals the segmentation results when
utilizing the proposed scheme. As seen in Figure 4-5 (e), the shape priors improve regularity
by allowing the snake to overcome various noise artifacts. This allows for proper delineation
of the left ventricular endocardial lining. Furthermore, the motion information (optical flow)
is used as structural information in the external energy of the snake.

57

(a)

(b)

(c)

(d)

(e)

Figure 4-5 Segmentation results; (a) LV echocardiogram, (b) SRAD diffusion of image
(a), (c) manual expert delineation of image (a), (d) and (e) segmentations when utilizing
GVF only and when utilizing the proposed scheme, respectively.
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4.4 Conclusions
In this work, we have shown that the use of optical flow estimations and SRAD diffusion
techniques perform well when integrated with a GVF active contour. This scheme helped
alleviate the inherent difficulties in segmenting echocardiograms, such as considering
speckle noise and contour bleeding. Furthermore, it strengthens the principle that tissue
movement should be considered within segmentation techniques, where the data facilitates it.
Contour regularity and accuracy were further improved by using primitive shapes priors. The
inherent difficulties in segmenting echocardiographic images, such as avoiding speckle noise
and valve interference were also overcome by the primitive priors. Results were validated
against a gold standard, which was manually segmented by a clinician and yielded stronger
results than the standard GVF snake in sensitivity, precision rate and overlap ratios. Such
segmentations would improve the calculation of various clinical measures by reducing the
inconsistencies and variability between clinicians while simultaneously reducing the time for
clinician interaction.
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Chapter 5
5 Clinical Sciences Introduction
"Clinical informaticians transform health care by analyzing, designing, implementing, and
evaluating information and communication systems that enhance individual and population
health outcomes, improve patient care, and strengthen the clinician-patient relationship."
Gardner RM et al. Core Content for the Subspecialty of Clinical Informatics
My journey continues onward.

Clinical Informatics is also sometimes referred to as health informatics. [1] It is the study and
use of data and information technology to deliver health care services and to improve the
patients’ ability to monitor and maintain their own health. This results in the definition of
new clinical practice guidelines and support for all clinicians, patients, and caregivers.
This field encompasses a wide array of research sub-categories, including:
•

Various methods to collect, store, and analyze health care data

•

The study of information needs and cognitive processes

•

Clinical decision support, including summarization, visualization, and provision of
evidence in novel ways

•

Information flow and workflow optimization

•

Policy creation for information infrastructure, together with privacy and security

•

Integration of systems and optimal solutions within healthcare facilities.

Statistical modeling methods were used in the presented clinical research methodologies. Of
these, the following are the most relevant to the presented integrated articles:
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Cluster analysis [2][3][4] or clustering is the task of grouping a set of objects in such a way
that objects in the same group (called a cluster) are more similar (in some sense or another)
to each other than to those in other groups (clusters).
Decision tree learning [5] uses a decision tree as a predictive model which maps
observations about an item (represented in the branches) to conclusions about the item's
target value (represented in the leaves). It is one of the predictive modelling approaches used
in statistics, data mining and machine learning.
Markov model [6] is a stochastic model used to model randomly changing systems where it
is assumed that future states depend only on the current state not on the events that occurred
before it (that is, it assumes the Markov property). Generally, this assumption enables
reasoning and computation with the model that would otherwise be intractable.
Stratification [7] is the process of dividing members of the population into homogeneous
subgroups before sampling. Each subgroup (or strata) should be mutually exclusive: every
element in the population must be assigned to only one stratum. The strata should also be
collectively exhaustive: no population element can be excluded.
I have selected four integrated articles in order to expose some of my clinical research
publications. In the previous chapters, I improve algorithms via novel pipelines to help
identify segments of an image, in these clinical articles, I create novel pipelines to improve
models for disease prediction and discovery.
In the first integrated article, which has been cited 8 times as of the submission of this thesis,
“Cluster Analysis of MR Imaging in Alzheimer’s Disease using Decision Tree Refinement”
[8], the use of novel analytical techniques (such as data clustering and decision trees) that can
model and predict patient disease outcomes is presented. This has great potential for
assessing disease process and progression in Alzheimer’s disease (AD) and mild cognitive
impairment (MCI). For this study, 124 different variables (generated from image data,
demographics and data) have been compiled and analyzed using a modified clustering
algorithm – by linking variable distance to outcomes. The testing samples included 112
healthy controls, 122 MCI patients, and 120 AD patients. Our aim was to determine the
influence of these variables on the incidence of Alzheimer’s and mild cognitive impairment.
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Furthermore, we used a decision tree algorithm to model the level of “importance” of
variants influencing this decision. These models demonstrate the influence and importance of
clinical, biomarker imaging and neuropsychological variables on the patient’s long-term
health.
In the second integrated article, which has been cited 2 times as of the submission of this
thesis, “A Markov Analysis of Patients Developing Sepsis using Clusters” [9], presents
predictive algorithms determining which patients are more likely to develop sepsis, in which
early treatment can potentially reduce their risks. This is difficult since there is no “standard”
presentation of sepsis, despite many published definitions of this condition. In this work, data
from a large observational cohort of patients (4196 patients were randomly selected) – with
variables collected at varying time periods – are observed in order to determine whether
sepsis develops or not. A cluster analysis approach is used to form groups of correlated data
points. This sequence of data points is then categorized on a per person basis and the
frequency of transitioning from one grouping to another is computed. The result is posed as a
Markov model which can accurately estimate the likelihood of a patient developing sepsis. A
discussion of the implications and uses of this model is presented.
In the third integrated article, “A Disease Registry and Disease Management System for
Patients with Malignant Melanoma” [10], a unique longitudinal tracking system for the
treatment and outcome management for patients with melanoma is presented. The system’s
design was informed by healthcare providers, a review of existing systems and published
literature. Strategies and interventions designed to better understand melanoma can help
reduce the risk and rate of the disease. Current registries and information systems are generic
in nature and not tailored to a specialist’s workflow or clinic needs. Efficient data collection
systems and application of effective workflow models can lead to significant improvements
in quality of healthcare. Several modules have been established to address the concerns of the
healthcare clinic, including: patient demographics, imaging, patient surveys, security,
reporting and analysis. This framework is capable of displaying disease imaging screens,
visually and interactively tracking melanoma sites, automatically computing staging scores,
and tracking all surgeries and outcomes. Conditional patient access provides an interactive
model of care to the clinic.
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Finally, in the last integrated article, “Burden of illness for metastatic melanoma in Canada:
2011–2013” [11], a detailed epidemiology for patients with advanced metastatic melanoma
in Canada was presented based on the data collection system presented above. The aim of
this study was to demonstrate the presentation, disease characteristics, course, and treatment
patterns for malignant melanoma patients. We used data collected via the Canadian
Melanoma Research Network (CMRN) Patient Registry. We identified patients who were
seen at one of 3 cancer treatment centres between April 2011 and April 30, 2013. A cohort of
810 patients with melanoma was identified from the CMRN registry. The mean age was 58.7
years and the majority were male (60% vs 40%). Factors impacting survival included having
unresectable or metastatic melanoma, initial stage at diagnosis, presence of brain metastasis,
and BRAF mutation status. The proportion of surviving patients decreased with higher initial
disease stages. Using the CMRN registry, we were able to determine detailed epidemiology
of patients with melanoma in Ontario, validating the comprehensive and detailed information
that can be obtained from these data when using efficient data collection.
This selection of works concludes my clinical research component and has provided me with
a window to continue future research studies in the realm of informatics.

5.1 Selection of Papers
The selection of these works demonstrates a progression from dealing with algorithmic
techniques and pipelines for improving the modeling and prediction of diseases. It progresses
and culminates in the collection of datasets and leveraging them for external parties to do
additional research. I have included some of the citations for these integrated articles, though
some of which have not been published long enough to be widely cited or leveraged. The
expectation of providing a data collection platform that houses granular and longitudinal data
sets (as in article 6) sets the stage for further research by external parties along with the
continued development of novel techniques and trend discovery for healthcare improvement.
Though the datasets leveraged in the following clinical articles contained medical images
from various modalities, the analyses were conducted on a full range of the available dataset,
including demographics, genetic, biomarker, etc. This allowed my algorithmic pipelines to
encapsulate a greater range of information when modelling outcomes.
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Article 4 provides my first view into clinical datasets, I developed a model and analysis
pipeline for Alzheimer’s disease which was used by other research students within the lab. In
order to validate the model, it was applied to a sepsis dataset, which is represented in Article
5. However, this second dataset was riddled with missing data, incomplete timelines and
erroneous segments. In order to accommodate the data and the desired output the model was
modified and generalized. Once I realized that clinical datasets were not being collecting
efficiently, I partook in building an informatics toolkit in order to provide longitudinal
datasets to other researchers, depicted in Article 6. Article 7 demonstrates some of the data
trends and outcomes generated from the collected datasets. This data has been leveraged by
at least three other research associates and will grow as the data becomes more complete and
robust.
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Chapter 6 – Article 4
6 Cluster Analysis of MR Imaging in Alzheimer’s Disease using
Decision Tree Refinement*
Abstract: The use of novel analytical techniques (such as data clustering and decision trees)
that can model and predict patient disease outcomes has great potential for assessing disease
process and progression in Alzheimer’s disease and mild cognitive impairment. For this
study, 124 different variables (generated from image data, demographics and data) have been
compiled and analyzed using a modified clustering algorithm. Our aim was to determine the
influence of these variables on the incidence of Alzheimer’s and mild cognitive impairment.
Furthermore, we used a decision tree algorithm to model the level of “importance” of
variants influencing this decision.
Keywords: Alzheimer's Disease, Mild Cognitive Impairment, Cluster Analysis, Decision
Tree Analysis, MRI
Subject Classification Numbers: CCS-H.3.3, CCS-J.3

6.1 Introduction
Mild cognitive impairment (MCI) may be defined as a transitional state between normal
aging and Alzheimer’s disease (AD) in which memory impairment is greater than expected
for age, but general cognitive function and daily living activities are preserved [12]. The rate
of progression from MCI to dementia is considerable according to estimates from several

*
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longitudinal studies: 12% per year for 4 years [12], 40% over 2 years [8], 53% over 3 years
[10], 34%–100% over 4–5 years [1, 9], and 100% over 9.5 years [11]. Currently, there is
much debate over whether MCI is a separate nosological entity at increased risk of dementia
or is an early symptom of AD [15]. Regardless, it is important to develop tools that enable us
to predict conversion from MCI into progressive dementia.
The early detection and management of this disorder is important due to the recent
availability of drug therapies for mild-to-moderate AD. As therapies with the potential to
arrest the progression of Alzheimer’s disease are being developed, identification of people
with pre-Alzheimer conditions has become increasingly important to determine whether such
individuals can benefit from pharmacologic and non-pharmacologic interventions.
Unfortunately, once fully developed, AD is a devastating illness with a long drawn-out
course that results in a diminished quality of life for patients and their caregivers. Treatment
strategies targeting the most susceptible individuals (either primary or secondary prevention)
are urgently needed. These strategies can provide a means of delaying the progression of the
disease to those that are at risk of converting from MCI to AD. Developing analytic tools to
support these goals is in the interest of the patient, health care provider and payers, as well as
research and development in the pharmaceutical industry. In order to refine treatment
strategies and establish early markers of disease, it is important to differentiate features that
are prevalent in AD and MCI.
This work deals with the use of modeling techniques to classify patients as AD and MCI,
which will improve clinical outcomes by providing an early assessment of potential AD
patients. This assessment can change the treatment plans of such patients, which could
impact the long-term progression of AD or MCI. Section 2 describes the systems, methods
and approaches used in detail and describes implications of the proposed model. Section 3
describes the analysis used on the datasets and Section 4 concludes and summarizes this
work.
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6.2 Systems and Methods
In order to address these goals, data from the AddNeuroMed study*, (which had institutional
review board approval), was used to accurately model AD and MCI. A rich imaging dataset
was available, which provided efficacy data and optimized patient selection. Data was
collected at baseline (time of recruitment) and then at three month and 12 months follow up
visits. In this paper, we describe the methodology used to differentiate patients at baseline.

6.2.1 Dataset Source
AddNeuroMed, a European AD biomarker study, aimed to perform a multi center MRI study
similar to that of a drug trial. MRI scans were collected and evaluated at a data coordination
centre (DCC) and were correlated to data from other sources (i.e. clinical datasets, data from
blood samples, etc). The clinical centers that participated in this study were King’s College
London, University of Thessaloniki, University of Kuopio, University of Perugia, Medical
University of Lodz and University of Toulouse. The DCC was the Karolinska Institutet in
Stockholm.
Data management, image quality control and workflow control were guided by the Loris
database platform (originally developed at McGill Brain Imaging Centre), and were further
customized in this work. Patients were selected based on criteria that established whether
they had MCI, AD or neither (i.e. controls). Patients were selected at each of the above
centres, and were continuously sampled until the accrual goals were met. Accrued subjects
consisted of a balanced sample with 112 healthy control, 122 MCI patients and 120 AD
patients.

6.2.2 Tissue Classification and Regional Segmentation
MRI data acquisition took place using six different 1.5T MR systems (4 General Electric, 1
Siemens and 1 Picker). At each site a quadrature birdcage coil was used for RF transmission
and reception. Data acquisition was designed to be compatible with the Alzheimer Disease
Neuroimaging Initiative (ADNI) [6]. The imaging protocol included a high resolution sagittal

*

This study was funded by the European Union of the Sixth Framework program priority FP6-2004-LIFESCIHEALTH-5,
Life Sciences, Genomics and Biotechnology for Health.

71

3D T1-weighted MPRAGE volume (voxel size: 1.1 * 1.1 * 1.2 mm3) and axial proton density
/ T2-weighted fast spin echo images. The MPRAGE volume was acquired using a custom
pulse sequence specifically designed for the ADNI study to ensure compatibility across
scanners [16,17]. Full brain and skull coverage was required for both of the latter datasets
and detailed quality control carried out on all MR images [16,17].
We adopted a three-stage approach to quality control. First, MRI scans were regularly
acquired at each of the sites using a urethane test object known as a phantom. A phantom
design developed by the U.S.-based ADNI consortium was used, which allows precise
quantification of the geometric accuracy of a scan, together with other quality control
measures, including signal-to-noise ratio and image uniformity using the ImageOwl webbased automated quality control system (http://www.imageowl.com) to ensure good
performance of each of the scanners during the duration of the study. Second, two volunteers
were scanned at each site, and their images were processed using the same analysis tools as
the cohort images to ensure compatibility of data [16,17]. Finally, the MRI sites and data
coordination center worked closely together with continuous feedback as data was acquired.
All MRI centers were trained to perform quality control at their site at the time the images
were acquired with particular emphasis on full brain coverage, image wrap around, subject
motion artifacts, contrast between gray and white matter, and image nonuniformities [16,17].
All scanners remained within specification for the ADNI phantom throughout the course of
the study. The coefficient of variation for whole brain measures for the two volunteers
scanned at each of the sites was 1.7% and the mean (sd) of the coefficients of variation for
the smaller anatomical regions reported in this paper was 3.4 (1.9)%.
All MR images received a clinical read by an on-site radiologist in order to exclude any
subjects with non-AD related pathologies such as brain tumors.
A highly automated structural MRI image processing pipeline which was developed by
Fischl and his colleagues was utilized for data analysis [3, 4, 5]. It produced both regional
cortical thickness measures and regional volume measures.
Cortical reconstruction and volumetric segmentation included removal of non-brain tissue
using a hybrid watershed/surface deformation procedure, automated Talairach
transformation, segmentation of the subcortical white matter and deep gray matter volumetric
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structures (including hippocampus, amygdala, caudate, putamen, ventricles) intensity
normalization, tessellation of the gray matter white matter boundary, automated topology
correction, and surface deformation following intensity gradients to optimally place the
gray/white and gray/cerebrospinal fluid borders at the location where the greatest shift in
intensity defines the transition to the other tissue class. Surface inflation was followed by
registration to a spherical atlas which utilized individual cortical folding patterns to match
cortical geometry across subjects and parcellation of the cerebral cortex into units based on
gyral and sulcal structure.

6.2.3 Variables
The T1 weighted images were used to measure structural changes in the brain. A total of 51
regional volumetric and 70 regional cortical thickness measures were determined. All
volumetric measures were normalized by dividing by the intracranial volume. Together with
age, gender and the e4 version of the APOE gene (a risk factor for Alzheimer’s disease) this
yielded 124 variables which were used for the proposed analysis. Table 1 summarises the
demographics of the three groups (Alzheimer’s disease, mild cognitive impairment and
controls).

6.3 Analysis
A cluster analysis algorithm was used in order to determine whether or not partitions,
representing AD or MCI states, within the AddNeuroMed dataset could be identified and
modeled for subsequent decision making. This technique was further refined using decision
trees in order to enhance the cluster predictor.

6.3.1 Cluster Analysis
Cluster analysis, or clustering, is the assignment of a set of observations into subsets (called
clusters) such that observations in the same cluster are of similar kind and grouped into
respective categories. Clustering is a method of unsupervised learning, and a common
technique for statistical data analysis. The clustering method used in this work was developed
to serve two purposes, the first was to expose the importance of each variable with respect to
the decision making process on the disease. The second was to provide a means of
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discovering, given the preliminary image data results, whether or not a subject was likely to
have MCI or AD based on cluster belongingness.
A variety of different clustering sizes and algorithms were explored. Empirically, the number
of clusters chosen was 12 – resulting in clusters that were neither too large to manage (over
fitted), nor ones with too few data points to give an adequate determination of patient status
due to lack of separation. A modified k-means clustering algorithm was used in this work due
to its speed of execution on large datasets. This algorithm incorporates both the internal
consistency of variables within the cluster (distance to the cluster’s centroid) and the external
distance to all neighboring clusters as its heuristic. The k-means algorithm used is refinement
iterative and alternates between assignment (where each variable is assigned to a cluster) and
updating (calculation of new means of the cluster centre). By doing so, clusters will
eventually incorporate all variables within the closest proximity space.
During cluster generation, the algorithm is applied to every variable within the dataset.
Variables are then ranked by influence and probability of defining a cluster and its location
within the cluster field (internal consistency measure). Following cluster creation, the cluster
fields are grouped based on the internal consistency of the variables within each cluster. The
mathematical indicator used to create these groupings is defined as the orthogonal distance
between clusters [14].
Since we know whether a patient belongs to the control, MCI or AD group, this information
(which is not used in cluster creation) is used to validate the biological plausibility of the
separation, in other words, test the cluster field specificity. Hence, the cluster field can be
used in order to determine which variable belongs to a respective group, given an internal
consistency measure.
Figure 6-1(a) displays a cluster field using the proposed technique with belongingness to the
groups indicated by colour. This was generated by using all of the variables (126 for the
AddNeuroMed study) available. This technique leads to nicely separated clusters, however
there is overlap between groupings (where primary red represents control, primary green
represents MCI, and primary blue represents AD). This is evident in Figure 6-1(a), since the
colours shown have amalgamated at various places within the proximity space. This is
known as grouping overlap within the clusters, and hence makes it difficult to accurately
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define what a cluster truly represents – rendering decision making complicated. Accurate
variable selection can lead to better defined clusters with less overlap in groupings. Since the
grouping results are known, a series of principal component analysis could be used to refine
the variables used. Though, since the ultimate goal of the cluster analysis is decision making,
decision trees are a more efficient means of refining this process to gain greater precision or
sensitivity.

6.3.2 Decision Trees
In order to determine which variables contribute to a higher internal consistency within a
cluster (i.e. the belongingness of a cluster to one outcome versus another), a decision tree
algorithm was used.
A decision tree is a predictive model, that is, a mapping from observations about an item
resulting in conclusions about its target value [13]. In these tree structures, leaves represent
classifications and branches represent conjunctions of features that lead to those
classifications. A decision tree is made from a succession of nodes, each splitting the dataset
into branches. Generally, the algorithm begins by treating the entire dataset as a single large
set and then proceeds to recursively split the set. Three popular rules are typically applied in
the automatic creation of classification trees. The Gini rule splits off a single group of as
large a size as possible, whereas the entropy and two-ing rules find multiple groups
comprising as close to half the samples as possible. The algorithms construct the tree from
the “top” down until some stopping criterion is met. In our current approach, we have used
the gain in entropy, which accurately models the physical system evolving spontaneously
toward equilibrium, in order to determine how to best create each node of the tree.
In order to define information gain precisely, we used a measure called entropy, that
characterizes the “purity” (or, conversely, “impurity”) of an arbitrary collection of examples.
Generally, given a set S, containing only positive and negative examples of some target
concept (the so-called two-class problem), the entropy of set S relative to this simple, binary
classification is defined as:
Entropy(S) = - pplog2 pp – pnlog2 pn

(1)
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where pp is the proportion of positive examples in S and pn is the proportion of negative
examples in S.
Given that entropy is a measure of the impurity in a collection of training examples, we can
then define the effectiveness of an attribute in classifying the data. The measure we will use,
called information gain, is simply the expected reduction in entropy caused by partitioning
the examples accordingly. More precisely, the information gain, Gain (S, A) of an attribute A,
relative to a collection of examples S, is defined as:
Gain( S , A)  Entropy( S ) 



vvalues( A )

Sv
Entropy( S v )
S

(2)

where values(A) is the set of all possible values for attribute A, and Sv is the subset of S for
which attribute A has value v (i.e., Sv = {s ε S | A(s) = v}). In other words, Gain (S ,A) is the
information provided about the target attribute value, given the value of some other attribute
A.
Continuous variables, such as temperature, require a somewhat special approach. This is
accomplished by dynamically defining new discrete attributes that partition the continuous
attributes into a discrete set of intervals. In particular, for an attribute A that is continuous, the
algorithm can dynamically create a new Boolean attribute Ac that is true if A < c and false
otherwise. The only question is how to best select the value for the threshold c. This is
accomplished by selecting values for the threshold based on the existing values of the
attribute A and computing the gain. The threshold c that produces the greatest information
gain is then chosen (as shown in Equation 3).
Result = max Gain(S , A)
cAi

(3)

The process of selecting a new attribute and partitioning the training examples is then
repeated for each non-terminal descendant node in the tree, only the training examples
associated with that node. Attributes that have been incorporated higher in the tree are
excluded, so that any given attribute can appear at most once along any path through the tree.
This process continues for each new leaf node until either every attribute has already been
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included along this path through the tree, or the training examples associated with this leaf
node all have the same target attribute value (i.e., their entropy is zero).
The customized decision tree algorithm is defined below, where:
Si represents the current working subset of the original dataset
A represents one attribute from the set Si.
The gain is calculated as described in Equation 2.
Algorithm Start
1.0
Initialize Si to be the full data set
2.0
While Si is not empty
2.1
Loop through select A in Si
2.1.1
If A is discrete
2.1.1.1
Compute the simple gain (handling missing values)
2.1.2
If A is continuous
2.1.2.1
Resolve missing values by substituting most common learned values
2.1.2.2
Find the best threshold for c resolving the maximum gain (eq. 3)
2.1.2.3
Substitute the discrete conversion of A (using c) and calculate gain
2.2
Select the A with the maximum gain
2.3
Split Si using the chosen A
Algorithm End

This algorithm would halt when Si has achieved the maximum number of splits. In order to
identify the leaves, the algorithm analyzes the structure of the remaining set. If the set
contains only one remaining type of data (or only a pre-set proportion of such types) no
further splits are required. Leaf nodes are created when the set Si splits with the same A
twice. An example of a resulting decision tree illustrating nodes of attributes between the
Alzheimer’s patients and normal control is shown in Figure 6-2.
For each grouping, the decision tree algorithm was run on the variables. During tree creation,
the variables with the greatest importance, based on external proximity between groups, were
used to create the branches. The probability at the resulting nodes indicated whether or not
that variable influenced a grouping. The variables that had an influence of greater than 80%
were allocated greater priority in cluster creation. By using the results of the decision tree
weights and applying them to the cluster analysis, Figure 6-1(b) shows an updated render of
the dataset on a 3D space proximity grid. It is apparent that the colours of Figure 6-1(b) are
elemental and hence represent a better separation of stages (MCI vs. AD).

6.4 Discussion and Conclusions
The utilization of clustering and decision trees has potential to provide models which
demonstrate the influence and importance of clinical, biomarker imaging, and neuro-
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psychological variables on a patient’s long term health. This research focused on exploring
whether such techniques could be applicable to MRI measures from AD and MCI. Using the
proposed techniques, we believe that it will be possible in the future to aid the early detection
of AD/MCI patients and allow the application of new drug therapies with the potential to
arrest or retard the progression of Alzheimer’s disease.
For this study, a modified k-means clustering algorithm was used to partition data into
control, MCI and AD sets. Decision tree models were used to identify the level of
“importance” of covariates within each cluster. The algorithm provided adequate separation
of groups where decision making is possible using this model. Consider the resulting cluster
analysis that is rendered in a 3D proximity space (eg. Figure 6-1(a)) where the colours are
distinct and their separation gives rise to a grouping). The legend indicates the percentage of
patients with a specific outcome within the group. Groups with greater than 80% of the
outcome provide insight into variables that tend to collect or accumulate together within that
group. Decision trees allow us to expose the strongest variables within each grouping and
hence give more weight to these variables during cluster creation.
Future improvements and refinements to the clustering algorithm will include the analysis of
each covariate, by calculating the distance of each variable to the centre of the cluster. Ours
is one of the first studies to consider clustering in order to help partition variables on the
basis of clinical and biological importance. The implications for future drug development and
application are supported by our early findings.
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(a)

(b)

Figure 6-1 Cluster analysis of AddNeuroMed dataset modeled on 3D space proximity
grid. (a) Full variable selection to create a cluster fields. (b) Using only the variables
determined to be of value by decision trees. (Implementations of clustering and
graphing were applied using C++ and Matlab)
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Figure 6-2: Decision tree comparison of normal patients and categorized Alzheimer’s
patients
Table 6-1: Demographics of AddNeuroMed dataset
Variable

Alzheimer’s Disease

Mild Cognitive
Control
Impairment
120
122
112
Number
77/43
63/59
63/49
Gender - F/M
Age
75.5 6.1
74.4 5.7
73.0 6.7
MMSE
20.9 4.8
26.8 3.0
29.0 1.2
0
CDR
1.2 0.5
0.5 0.1
Years of Education
8.1  4.0
8.9 4.3
10.7 4.8
Data is represented as average ± standard deviation, MMSE = Mini Mental State
Examination, CDR = Clinical Dementia Rating (validated measures).
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Chapter 7 – Article 5
7 A Markov Analysis of Patients Developing Sepsis using
Clusters*
Abstract: Sepsis is a significant cause of mortality and morbidity. There are now aggressive
goal oriented treatments that can be used to help patients suffering from sepsis. By predicting
which patients are more likely to develop sepsis, early treatment can potentially reduce their
risks. However, diagnosing sepsis is difficult since there is no “standard” presentation,
despite many published definitions of this condition.
In this work, data from a large observational cohort of patients – with variables collected at
varying time periods – are observed in order to determine whether sepsis develops or not. A
cluster analysis approach is used to form groups of correlated data points. This sequence of
data points is then categorized on a per person basis and the frequency of transitioning from
one grouping to another is computed. The result is posed as a Markov model which can
accurately estimate the likelihood of a patient developing sepsis. A discussion of the
implications and uses of this model is presented.
Keywords: Sepsis, Markov Chains, Cluster Analysis, Predictive Modelling.

7.1 Introduction
Sepsis is defined as an infection with systematic manifestations of an infection [7]. Severe
sepsis is considered present when sepsis co-exists with sepsis-induced organ dysfunction or
tissue hypoperfusion [7]. This can result in mortality and morbidity, especially when
associated with shock and/or organ dysfunction [3]. Sepsis can be associated with increased
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A version of this chapter has been published: Femida Gwadry-Sridhar, Michael Bauer, Benoit Lewden, Ali
Hamou. “A Markov Analysis of Patients Developing Sepsis Using Clusters”, Knowledge Representation for
Health-Care. KR4HC 2010. Lecture Notes in Computer Science, Springer. 2011, vol. 6512.
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hospital resource utilization, prolonged stays in intensive care units (ICU) and hospital
wards, decreased long-term health related quality of life and an economic burden estimated at
$17 billion USD (equivalent to $17.49 billion CAD) each year in the United States alone [5,
17, 21]. In Canada, there is limited data on the burden of severe sepsis; however, costs in
Quebec may be as high as $73 million CAD per year [13] which contributes to the estimate
of total Canadian cost of approximately $325 million CAD per year.
Patients with severe sepsis generally receive their care in an ICU. A multinational study of
sepsis in teaching hospitals found that severe sepsis or septic shock is present or develops in
15% of ICU patients [1]. However, diagnosing sepsis is difficult since there is no “standard”
presentation despite many published definitions for sepsis [2, 14]. In the STAR registry [15]
(containing a mix of teaching and community hospitals across Canada), the total rate for
severe sepsis was 19%. Of these, 63% occurred after hospitalization.
The management of severe sepsis requires prompt treatment within the first six weeks of
resuscitation [7]. Intensivists currently support the use of early goal-directed resuscitation of
patients. This has shown to improve survival in patients presenting to emergency rooms with
septic shock [7].
Given the many advances in medicine today, there now exist aggressive goal oriented
treatments that can be used to help patients with sepsis and severe sepsis [4, 16, 18]. If
researchers could predict which patients may be at risk for sepsis, treatment may be started
early and potentially reduce the risk of mortality and morbidity. Therefore, methods that help
with the early diagnosis of patients who either have or are at risk for sepsis within hospitals
are in dire need and in fact may result in better prognosis if interventions are initiated early.

7.1.1 Analytic Techniques
A variety of analytical techniques can be used to establish relationships and assess the
strength of these relationships among a set of measured variables or quantities. Researchers
commonly use univariate or multivariable regression models to estimate the association
between prognostic variables and a clinical outcome (such as sepsis). Multivariable
regression models are frequently used in studies where clinical outcomes are included. These
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models can use both categorical and continuous variables, but the use of uncritical modeling
techniques can lead to erroneous conclusions and resultant imprecision [9].
In this work, our primary goal is to determine patients at risk of a particular clinical diagnosis
– sepsis being the reference case. Many approaches exist for analyzing patients with and
without sepsis [8]. These approaches generally use regression models, which assume the
existence of an identifiable, singular set of variables (or variables) for prediction. Hence, if
there exist multiple sets of variables that appear in several independent traits, then prediction
with this method becomes difficult. The current literature illustrates some of the limitations
with univariable and multivariable models [8, 18, 19]. In order to address such limitations,
alternative approaches to simplify the multi-faceted nature of predicting sepsis need to be
investigated.
In this paper, we construct a Markov model to predict sepsis using patient data from 12
Canadian Intensive Care Units (ICU’s). Our model differs fundamentally from those
previously used for predicting an outcome. Outcome probabilities are generated by the use of
a k-means cluster analysis algorithm to group variables into correlated datapoints and then
use these to define the “states” in a Markov model. Transitions in the model are determined
based on successive values of the datapoints for individual patients. The transition model
assumes that patient’s risk changes dependent on their state of health.
Section 2 describes the approach in detail and depicts examples and implications of the
proposed model. Section 3 describes the results and Section 4 explores the model’s
repercussions and future initiatives. Section 5 concludes and summarizes this work.

7.2 Methods
7.2.1 Data Acquisition
We obtained data that was collected from 12 Canadian ICU’s that were geographically
distributed and included a mix of medical and surgical patients [15]. The study was approved
by the University of Western Ontario Research Ethics Board and the need for informed
consent was waived. Data was collected on all patients admitted to the ICU who had a stay
greater than 24 hours or who had severe sepsis at the time of admission. Patients who did not
receive active treatment were excluded. We screened over 23,000 patients for sepsis (of
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which 4,196 were randomly selected for this study). Patients with confirmed sepsis were
classified as “septic.” It is normal practice in the ICU to treat patients with suspected sepsis
as septic until blood cultures are available.
Hospitals routinely collect a minimum data profile on all eligible patients admitted to the
ICU [6]. This includes demographic information, admission data, source of admission,
diagnosis, illness severity, outcome and length of ICU and hospital duration. Table 1 presents
a summary of the variables collected in this data profile for this study. This table also shows
the influence of each variable on sepsis output when analyzed with a simple logistic
regression model (since the variables were Boolean – or binary in terms of the analysis).We
have previously reported this analysis. [8]. Illness severity scores were calculated using a
validated formula from data obtained during the first 24 hours in the ICU [11, 12]. All
patients were subsequently assessed on a daily basis for the presence of infection and severe
sepsis. Hence, for patients with stays longer than 24 hours, a repeated measures of the
variables in Table 1 were collected and averaged on their daily condition. The characteristics
of the variables are a part of standard ICU testing protocol and have been described
elsewhere [15].

7.2.2 Model Formulation
Our patient data is modeled in the following format:
p1 : d11, d12, …, d1n1
p2 : d21, d22, …, …, …, d2n2
p3 : d31, d32, …, …, d3n3
......
where pi represents a patient in our data set, and dij represents a datapoint, each consisting of
measurements for the 25 variables identified in Table 1 (where i represents the patient and j
represents the data collection variable). A non-predetermined number of datapoints hence
exists for each patient. These datapoints progressed time-wise from initial admittance to the
ICU/ward until departure or death. The time period between datapoints typically fell on
consecutive days, though this was not always the case (dependent on hospital protocols and
staff availability).
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Table 7-1: Sepsis Study: 25 variables collected to form a single datapoint
Variables
Anaerobia culture
Abdominal diagnosis
Blood diagnosis
Lung diagnosis
Other diagnosis
Urine diagnosis
Chest X-ray and purulent sputum
Gram negative infection culture
Gram positive infection culture
Heart rate > 90bpm
No culture growth
PaO2/FiO2 < 250
pH < 7.30 or lactate > 1.5 upper normal with base
deficit > 5
Platelets < 80 or 50% decrease in past 3 days
Respiratory rate > 19, PaCO2 < 32 or Mechanical
ventilation
SBP < 90 or MAP < 70 or Pressure for one hour
Abdominal culture
Blood culture
Lung culture
Other site culture
Urine culture
Temperature < 36 or > 38
Urinary output < 0.5 mL/kg/hr
WBC > 12 or < 4 or > 10% bands
Yeast culture
Constant

P value
0.122
0.000
0.000
0.000
0.000
0.000
0.000
0.047
0.001
0.000
0.000
0.000

Exp(B)
0.317
15.027
3.574
10.360
8.492
7.280
2.756
0.679
0.533
16.933
0.103
12.305

0.141

1.242

0.000

5.665

0.000

8.866

0.000
0.259
0.000
0.724
0.614
0.100
0.000
0.000
0.000
0.011
0.000

9.963
1.872
2.311
0.932
0.869
1.450
8.246
3.166
6.281
0.492
0.000

Analysis of the collected data was especially challenging for several reasons:
•

The number of datapoints per patient varied. For instance, some patients had two or
three datapoints, while for others there was a dozen or more.

•

The time periods between datapoints for a patient occasionally varied.

•

The conditions of patients when admitted were extremely diverse; some were severely
ill, already showing signs of sepsis, while others showed none. Hence, the first
datapoint of two separate patients would not correspond to the same stage of illness.

Clustering. Since the datapoints across the patient dataset is not aligned, as stated above, we
had to address this by considering all datapoints independently for an initial cluster analysis.
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In our previous work [8], cluster analysis had been used to group patients with and without
sepsis based on their initial datapoint. This proved to be a useful approach for grouping
patients. In this instance, the clustering would group similar datapoints as well – one could
consider the datapoints within the same cluster as representing the same “state” of a patient.
That is, similar datapoints would be clustered regardless of their position within a timeframe
for an individual patient. Though not considered in this initial clustering algorithm,
timeframe measurement data will be considered when such datapoints are placed within the
Markov model.
A variety of different clustering sizes and algorithms were explored. Data clustering
algorithms can be hierarchical. Hierarchical algorithms find successive clusters using
previously established clusters. Hierarchical algorithms can be agglomerative ("bottom-up")
or divisive ("top-down"). Agglomerative algorithms begin with each variable as a separate
cluster and merge them into successively larger clusters. Divisive algorithms begin with the
whole set and proceed to divide it into successively smaller clusters.
A modified k-means clustering algorithm (which was modeled to be agglomerative) was used
in this work due to its speed of execution on large datasets (over hierarchical for instance).
This algorithm incorporates both the internal consistency of variables within the cluster
(distance to the cluster’s centroid) and the external distance to all neighboring clusters as its
heuristic. The k-means algorithm used is refinement-iterative and alternates between
assignment (where each variable is assigned to a cluster) and updating (calculation of new
means of the cluster centre). By doing so, clusters will eventually incorporate all variables
within the closest proximity space. In general, the correct choice of k (being the number of
clusters) is often ambiguous, with interpretations depending on the shape and scale of the
distribution of points in a data set and the desired clustering resolution of the user. However,
for this study the number of clusters was chosen to be 12 – resulting in clusters that were
neither too large to manage (over fitted), nor ones with too few datapoints to give an
adequate determination of patient status due to lack of separation. k was achieved by
examining the percentage of variance of a function of the number clusters. Hence, adding
greater than 12 clusters didn’t achieve better modeling of the results given the modifications
to the clustering algorithm (i.e. custom distance measures).
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During cluster generation, the algorithm is applied to every variable within the dataset.
Variables are then ranked by influence and probability of defining a cluster and its location
within the cluster field (internal consistency measure). The mathematical indicator used to
create these groupings is defined as the orthogonal distance between clusters. Each variable
was essential a discrete point in a space which has its own dimension and base (the
dimension of each variable is simply the number of categories available). For example, if a
variable can take two distinct values then our base for this space becomes (1,0)(0,1). These
two vectors are orthogonal to each other and therefore are a base for this particular space.
Since our datapoints were binary categorized, each binary variable was normalized along its
matrix length and squared. Furthermore, in the event of datapoints that were equidistant to
multiple centroids, the internal consistency of each cluster was measured and the tighter field
was chosen. This prevented the ballooning of the cluster sets. Based on this consistency
measure, each cluster is labelled either sepsis or non-sepsis depending on the different
distributions of the datapoints within.
The algorithm behaves very close to the standard k-means algorithm:
•

Initialization:
o

Select first datapoint as the first centroid.

o

Calculate distance between centroid and all other points, select the furthest point as
second centroid (based on the distance calculated above).

•

o

Choose the furthest point from the first two centroids as the third.

o

Continue until N centroids (clusters) are achieved.

Iterate:
o

Each datapoint is sent to its closest cluster.

o

Recalculate cluster centres. (The centre minimizes the distance from itself and each
point. Hence, the distance between the centre and each point is minimized by
assigning it the most common category among its cluster).

o

Repeat until no change

The proposed algorithm also varies by compensating for “attraction points” such that clusters
smaller than 0.05% of the total size were removed at the end of each iteration and a new
centroid was determined based on calculating the point furthest away from the other
centroids. Furthermore, datapoints containing missing values were not considered suitable
candidates for any centroid positions.
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Markov Model. Following the cluster computation, each individual patient within the
dataset was analyzed. The individual datapoints, for instance, d11, d12, …, d1n1, were
considered separately. If d11 was in cluster Ci and d12 was in cluster Cj, then a transition from
Ci to Cj was created. The frequency of each transition was also tracked and so the total
number of transitions from Ci to any cluster, including Ci could be determined. This resulted
in each cluster being considered its own “state” and revealing the probability of a transition
from one cluster to another. Hence neighbouring datapoints will be represented by the
transitions between states.
All transition points were created by comparing each datapoint to every other datapoint
occurring in the future. This provides a temporal compliance (or normalization), such that the
time between d1 - d3 for a patient might be the same as the time between d1 - d2 for another
patient (or that the evolution of the infection during this “period” could be the same, in other
words the duration of d1 - d3 may equate d1 - d2.)
In order to complete the model, the following metrics were also recorded for each datapoint
within a cluster: (a) whether the patient did or did not have sepsis; (b) whether this was the
last datapoint associated with the patient or not and if it was the last datapoint what the
outcome was – namely discharged or deceased.

7.3 Results
A Markov graph with 14 states – 12 states corresponding to the clusters and 2 additional
states – one for patients that had been discharged (Alive as represented in Figure 7-1) and
one for those that were deceased was generated. The partial model for one Markov transition
graph is represented by the in Figure 7-1. (The remaining 11 transition graphs were left out
for efficiency and clarity – however they can be seen in the originally published work).
Transitions are represented by arrows to the new states (which are demarked as “Clusters”).
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Figure 7-1: Markov transition graph represented by first cluster
However, in order to simplify an explanation of the results, Figure 7-2 illustrates a portion of
the graph for 3 states: states #1, #5, and #6. The two final gray nodes represent the
“deceased” state and the “discharged” state. What is not shown in the graph is the percent of
patients that had been diagnosed with sepsis at the time their datapoints were included. These
are 0.3%, 35.0% and 90.18% for nodes #1, #5 and #6, respectively.
Note that a significant portion (57.8%) of the datapoints that were assigned to state #1, were
followed by their adjacent datapoint which was also assigned to state #1. Given the very low
percentage of patients diagnosed with sepsis within this cluster, this is likely a state
indicative of patients being admitted, never developing sepsis symptoms, remaining for
several days, and finally being discharged.
Node #5 can be considered representative of a patient developing sepsis (hidden or apparent,
depending on variable characteristics), or a patient recovering from it, as most patients have a
35% chance of sepsis in this state. It is not relevant which, as the model will provide a
predictor to which its next state will be.
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Node #6 represents a state which can be thought of as one characterizing a patient with
sepsis, since 90.18% of the patients having datapoints in this cluster were diagnosed with
sepsis. Interestingly, 25.9% return to state #1, where relatively few patients were identified
with sepsis. It is also interesting to note that from state #6 no patients died or were
discharged. This is likely due to aggressive treatment of sepsis when symptoms become
severe and apparent.

Figure 7-2: Portion of Markov Graph

7.3.1 Further Implications
There are many clinical applications where this model can be used. Consider the following
scenario where there exists a datapoint (the 25 variable set) for a patient admitted to an ICU.
This datapoint can be matched to a cluster, i.e., a “state”. From this state in the model, the
probability of the patient transitioning to a new state can be determined at the next “time
point”. For each “next state”, there exists a probability that the patient will develop sepsis.
Order is not implied in the model and is left to the transition probabilities, giving rise to a
powerful predictor. Finally, the likelihood of the patient developing sepsis by summing over
all possible transitions can easily be computed.
For example, assume that Figure 7-1 represents the entire Markov graph. If a patient’s
datapoint ends up in state #1, the patient’s estimated probability of developing sepsis is
calculated as follows:

91

Probability of Sepsis = 0.578*0.0129 + 0.0025*0.3504 + 0.0049*0.9018
= 0.012648, or 1.26%
This is only a one-step approximation – since it only considers a transition from state #1 to
its adjacent states by multiplying the transition probabilities by the state sepsis ones. In this
example, the one-step approximation illustrates the probability of the patient developing
sepsis using paths of length one. In general, one could compute paths of any length (limited
by the longest stay of any patient in the hospital in the dataset). Similarly, the probability of a
patient not developing sepsis, becoming discharged or becoming deceased, can also be
computed using the same algebraic technique.

7.3.2 Validation
In this study, 4,196 patients were selected in order to test the accuracy of the proposed
method. In total, 23,547 datapoints were available from the patient dataset. Testing the
precision of the clustering was achieved by first randomly selecting 10% of the datapoints
and removing them from the dataset for testing. Cluster generation followed by training on
this sub-sampled dataset, and testing on the removed datapoints, by matching them to the
trained clusters. These datapoints were then analysed to see whether they were repatriated to
a cluster that represented their end state (sepsis versus non-sepsis) – as if they were part of
the original training set.
For sepsis patients, an 80.01% precision rate was achieved (when recursive training and
testing was applied to the datapoints during cross-validation – in this instance, 1000
datapoints were swapped for each train/test run). For non-sepsis patients, a 94.69% precision
rate was achieved, partly because non-sepsis patients represented a larger sample size
throughout.

7.3.3 Future Work
The proposed technique will be thoroughly tested against other ICU patient cohorts in
Europe. Clusters will be used in conjunction with decision trees models in order to identify
which variables truly influence the development of sepsis versus non-sepsis in patients.
Furthermore, the non-homogeneous feature-based classification ability of decision trees and
the temporal break sequence modeling based on the Markov process should improve results
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significantly. Kim and Oh’s [10] proposed algorithm will be modified and utilized in future
works to further improve the model.

7.4 Conclusions
Multiple methods of analyzing clinical data provide different perspectives on assessing
patient health. We have demonstrated the use of cluster analysis as an efficient and relatively
swift method for identifying patients at risk – or not at risk – of a clinical condition, being
sepsis. The reliability and the validity of these clusters increases based on sample size and
based on testing across different datasets. Cluster analysis can be used as an effective tool to
supplement the daily monitoring of patients. By utilizing the transitioning probabilities
through a Markov model, clinicians can have a greater awareness regarding a patient who is
no longer at risk of contracting sepsis. This gives the clinician the ability to make a more
informed decision on treatment. Utilizing multi-faceted mathematical modeling is a useful
clinical informatics approach to support clinical decision making, the utilization of evidence
based treatment and efficiencies in health resource utilization.
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Chapter 8 – Article 6
8 A Disease Registry and Disease Management System for
Patients with Malignant Melanoma*
Abstract: Strategies and interventions designed to better understand melanoma can help
reduce the risk and rate of the disease. Current registries and information systems are generic
in nature and not tailored to a specialist’s workflow or clinic needs. Efficient data collection
systems and application of effective workflow models can lead to significant improvements
in quality of healthcare. We have developed a unique longitudinal tracking system for the
treatment and outcome management for patients with melanoma. The system’s design was
informed by healthcare providers, a review of existing systems and published literature.
Several modules have been established to address the concerns of the healthcare clinic,
including: patient demographics, imaging, patient surveys, security, reporting and analysis.
This framework is capable of displaying disease imaging screens, visually and interactively
tracking melanoma sites, automatically computing staging scores, and tracking all surgeries
and outcomes. Conditional patient access provides an interactive model of care to the clinic.
Keywords: Information storage and retrieval; Electronic health record; Information systems

8.1 Introduction
The past decade has seen a dramatic increase in the incidence of malignant melanoma, with
an estimated 1.97% of people being diagnosed within their lifetime [1-5]. As the leading
cause of death from skin disease, malignant melanoma accounts for approximately 1.2% of
all cancer death with an estimated 8,790 disease-related deaths in 2011 [4,6,7].

*

A version of this chapter has been published: Ali Hamou, Stacey Guy, Alexandria Ratzki-Leewing, Jesse
O’Brien, Femida Gwadry-Sridhar, “A Disease Registry and Disease Management System for Patients with
Malignant Melanoma”, AHIC – Advances in Health Informatics Conference, 2012.
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Despite efforts to allay the impact and incidence of melanoma, disease-related mortality has
remained relatively unimproved over the past decade. The current 5 year survival rate for
people with advanced disease, or who have relapsed after initial treatment is less than 5% [2].
Strategies and interventions designed to better understand melanoma can help reduce the risk
and rate of the disease.
The growing complexity of medical care has triggered the use of computers for acquisition,
storage, and retrieval of medical information. Efficient data collection systems and
application of effective workflow models can lead to significant improvements in the quality
of healthcare, namely an increase in patient safety and a reduction in healthcare costs [8-12].
Most electronic patient record platforms are generic in nature (i.e. are not based on specialist
workflow) creating cumbersome controls for specific clinic needs. By developing a platform
with these characteristics in mind, we have created a platform that inherently improves the
patient clinical experience and facilitates direct patient engagement through the use of
portals.
Utilizing these building blocks we designed an electronic, longitudinal tracking system for
the treatment and outcomes management for patients with melanoma. We felt that the data
collection and analysis facilitated by this system could provide critical data markers that help
improve the care of clinical processes.
This paper describes the development and design of an electronic clinical management
system for a melanoma clinic in Ontario, Canada.

8.2 Methods
8.2.1 System Design
We have developed a longitudinal data tracking framework which utilizes a MySQL backend
database management system (DBMS) and PHP with an AJAX front end web platform. We
established several modules to address the concerns of healthcare institutions including:
patient demographics, imaging, patient surveys of patient important outcomes, security and
secure authentication, reporting, and analysis. To establish relevant data parameters, we
worked with an oncologist with expertise in this area; conducted a review of the literature
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and reviewed other melanoma data collection systems, globally. Data was collected on
patients, registration, diagnosis, pathology (with imaging), staging, treatment, surgeries,
sentinel node biopsies, node dissection, radiotherapy, systemic therapy, outcome and/or
follow-up, and current patient status.
By creating a high quality interactive customized workflow based on intuitive data collection
screens and a clinical tracking tool, we have helped standardize the data representation
similar to a standard melanoma clinical workflow. This approach helps minimize tool
adoption rate times and reduces the need for paper-based tracking systems, reducing data
entry errors and increasing clinical efficiency. Our system is capable of displaying disease
imaging screens, visually and interactively tracking melanoma sites, automatically
computing staging scores, and tracking all surgeries and outcomes. Conditional patient
access provides an interactive model of care to the clinic.

8.2.2 Collecting Patient Information
In a traditional system, baseline information is typically manually collected by a healthcare
provider. These forms are transcribed or coded into an electronic database of patient records.
Direct data entry leads to various quality control issues. To address this challenge, our lab
designed the platform to be used not only with kiosk systems, but with web capable tablet
systems as well.
We have established various techniques to improve quality control and to ensure accuracy of
patient records. First, demographic data can be directly imported into the database onsite by
the patient or nurse. Second, field validation is used to ensure that no data is missing or
incorrectly filled (i.e., values out of permissible range). Administrators are able to designate
these fields and form validation on each entry. Third, data collection forms are clinical
workflow oriented, with built-in data validation (data flagging), auto-complete, and
dropdowns to facilitate fewer entry mistakes as shown in Figure 8-1. The resulting increase
in quality control ensures accurate patient record entry—the more accurate the demographics,
the more accurate the statistical analysis.
Figure 8-1 shows clinical workflow oriented data collection forms with auto-complete and
dropdowns for fewer entry mistakes as well built-in data validation (data flagging).
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Figure 8-1: Data collection forms
A patient portal module was also created to collect and easily store feedback and data on
patient quality of life. Based on the results of the quality of life survey (filled out by each
patient), educational information is displayed back to the patient regarding disease-specific
issues such as the effects of their medications. This module can also be used to collect and
monitor patient knowledge, medication compliance, satisfaction with the platform, and
health-related quality of life. Additionally, patients can use this module to visually indicate
the location of any pain which can be viewed by a clinician to determine cause and treatment.
These surveys can be completed in a patient waiting room using either a web-enabled tablet
or kiosk—these devices can be reserved for waiting rooms and used to simultaneously collect
patient feedback, educate patients on their illness, and even indicate to patients when the
clinician is ready to see them. Patients can also provide an email address or mobile phone
number so they can continue to receive educational material after their visit.
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8.2.3 Imaging
An imaging platform with all associated patient diagnostic images is located within each
patient record (Figure 8-2). By including images in the electronic patient record our platform
provides an additional layer of comprehensiveness. Clinicians can access the platform and
analyze the images with all associated test results to verify findings; images are
downloadable to a clinician’s personal device if further analysis is required. Users can also
highlight and focus on selected areas of the image via simple imaging tools such as magnify
and reorient. The interactive visual displays of our platform offer screen demarcation of
melanoma site, variable sizing and coloring option, and information regarding initial
diagnosis. A collapsible on-screen imaging module accompanied with information and
measurements is available for pathology and the general patient.
Figure 8-2 shows a collapsible on-screen imaging module accompanied with the
measurements related to the images being shown.

Figure 8-2: Imaging for pathology and general patient

8.2.4 Access and Security
The platform utilizes sftp and https (SSL-enabled authentication) encrypted pages to prevent
intrusion from external malicious attacks. A social access control mechanism was also
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established within the system to prevent internal attacks; this was partially accomplished by
assigning each user with a level of access within their domain. A hospital grade firewall
housed and secured the internal database and all data was backed-up nightly in case of failure
or corruption; system retractibility is also ensured by tracking and logging all database
actions via transactions.

8.2.5 Reporting and Analysis
The platform supports reporting and analysis features, which can display any dataset in
various forms for ease of representation. The analysis module of the platform provides realtime on-demand Staging frequencies on patients, filtering options on stage, information on
medication and complications; and customizable graphing and plotting interfaces (Figure 83). In the event that the built-in tools do not have the desired functionality, datasets in
various common formats (CSV, Excel, SAS) can be extracted for further analysis of patterns
and trends.
Figure 8-3 shows real-time on-demand Staging Frequencies on patients with filtering options
on stage, drug, complications etc. and customizable graphing and plotting interfaces.

8.3 Conclusions
Developing and establishing effective and dynamic data collection systems can lead to the
elimination of physical chart-pulls; a reduction in medical errors and prescription
clarification with pharmacies; the implementation of electronic review of patient medical
history from a single, accessible location; the notification of required tests, exams, or followups for patient care; an improvement in reporting on patients and practices and
communications between healthcare personnel; and the trending of patient vital and/or test
results.
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Figure 8-3: Analytics Module
Electronic data collection has the potential to significantly improve the quality of today’s
healthcare systems leading to improved patient safety and reduced healthcare costs [10-12].
However, while digitized systems enable easier and more efficient data extraction than
traditional manual systems, it is important to promote the standardization of backend systems
and to ensure that data not be held in silos and defined by large legacy systems where
valuable information can remain uncultivated.
Our platform provides an interface for data subsets within a common platform view. By
providing an interface for imaged data (X-RAYS, MRIs, CT scans etc.), we can use
conventionally recorded clinical data to enhance review and analysis. Additionally, our
interface can help inform clinical decision making by conducting preliminary disease or risk
modeling using multiple datasets with other relevant databases.
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Chapter 9 – Article 7
9 Burden of illness for metastatic melanoma in Canada: 2011–
2013*
Abstract: Background - Detailed epidemiology for patients with advanced metastatic
melanoma in Canada is not well characterized. We conducted an analysis of patients with
this disease in the province of Ontario, with the aim being to study the presentation, disease
characteristics and course, and treatment patterns for malignant melanoma.
Methods - In this Canadian observational, prospective, and retrospective study of patients
with malignant melanoma, we used data collected via the Canadian Melanoma Research
Network (CMRN) Patient Registry. We identified patients who were seen at one of 3 cancer
treatment centres between April 2011 and April 30, 2013. Patient data from 2011 and 2012
were collected retrospectively using chart records and existing data in registries. Starting
January 2013, data were collected prospectively. Variables investigated included age, sex,
initial stage, histology, mutation type, time to recurrence, sites of metastases, resectability,
and previous therapies.
Results - A cohort of 810 patients with melanoma was identified from the CMRN registry.
The mean age was 58.7 years and the majority were male (60% vs 40%). Factors impacting
survival included having unresectable or metastatic melanoma, initial stage at diagnosis,
presence of brain metastasis, and BRAF mutation status. The proportion of surviving patients
decreased with higher initial disease stages.

*

A version of this chapter has been published: Scott Ernst, Teresa Petrella, Anthony Joshua, Ali Hamou,
Marroon Thabane, Sharon Vantyghem, & Femida Gwadry-Sridhar. “Burden of illness for metastatic melanoma
in Canada, 2011–2013”. Current Oncology, 2016 vol. 23(6), pp. 563-570.
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Conclusions - Using the CMRN registry, we were able to determine detailed epidemiology
of patients with melanoma in the Canadian province of Ontario, validating the
comprehensive and detailed information that can be obtained from these data.
Keywords: Metastatic melanoma, epidemiology, burden of disease, cancer registry

9.1 Introduction
Melanoma is a malignant tumour that arises from melanin-producing cells called
melanocytes [1-4]. Approximately 90% of melanoma are cutaneous, but they can also occur
at any anatomical location (eg, eye, mucosal, head and neck surfaces, and along
gastrointestinal and genitourinary tracts) [2,5,6]. Cutaneous malignant melanoma (CMM) is
responsible for the vast majority (60% to 80%) of skin cancer-related deaths [4,7-11]. It was
estimated that in 2012, over 232,000 people worldwide were diagnosed with CMM and over
55,400 died of this disease [12]. In Canada, an estimated 6,800 new cases of cutaneous
melanoma and 1,150 related deaths are predicted for 2015 [13]. In addition, evidence
suggests that the incidence of CMM across Canada is increasing, a trend that has also been
seen in other countries worldwide [13-20].
The average 5-year survival rates are 90% and up to 70% for patients presenting with stage I
or II disease, respectively [2,11]. Traditionally, survival rates fell to approximately 40%
amongst those diagnosed with stage III melanoma, whilst the 1-year survival rate after stage
IV melanoma diagnosis was 26% [2,21,22]. Patients with stage IV disease have very poor
prognosis, with fewer than 10% alive at 5 years [2,23-26], although recent advances in
targeted and immunotherapies have significantly improved these numbers [27-32]. Although
the activity of targeted therapies and immunotherapies in melanoma have been promising,
the prognosis for long-term, disease-free survival among those with metastatic and recurrent
disease remains poor [33,34]. Thus, there remains an urgent unmet medical need for effective
therapies in patients with advanced melanoma.
The objectives of this study were to determine the presentation, disease characteristics,
disease course, and treatment patterns of CMM in Ontario.
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9.2 Methods
9.2.1 Epidemiologic Analysis: Melanoma-Related Disease Characteristics
This was a Canadian multicentre, observational, prospective, and retrospective study of
patients with CMM, using data collected from the Canadian Melanoma Research Network
(CMRN) Patient Registry. Patients with CMM who were seen at 1 of 3 cancer centres were
identified between April 2011 and April 30, 2013. Patient data were collected retrospectively
in 2011 and 2012 using chart records as well as existing data in registries, and all data from
January 2013 onward were collected prospectively. The study investigated disease
distribution among patients with melanoma according to age, sex, body region, tumour site,
initial stage, histological classification, mutation type, time to recurrence, sites of metastatic
disease, resectability, and previous adjuvant and systemic therapies. All patients with
confirmed melanoma and at least 12 months of follow-up data who were seen at any 1 of the
3 participating treatment centres were eligible for entry into the study. Patients who had less
than 12 months’ follow-up could be included, provided they were defined as such. Patients
without histological confirmation of melanoma were excluded.

9.2.2 Statistical Methods
Logistic regression models used for survival analysis were generated with survival at 1 year,
survival at 2 years, disease-free survival at 1 year, and disease-free survival at 2 years as
dependent binary variables, and a selection of variables, which included patient age and sex,
body region, stage, and BRAF mutation status, as independent variables.
All analyses were 2-tailed, with P < .05 set as the threshold for statistical significance, except
for inclusion/exclusion of variables in multivariate models, for which P < .10 was used.
Statistical analyses were performed in consultation with the principle investigators, using
SPSS version 20 statistical software (IBM Corp, Armonk, NY, USA).

9.3 Results
9.3.1 Patient Characteristics
From the CMRN Patient Registry, a cohort of 810 patients with CMM, diagnosed from 1964
to 2013 at 3 urban cancer treatment centres in Ontario, was identified. Patient characteristics
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are detailed in Table 9-I. The cohort had a mean age of 58.7 ± 14.8 years and was
predominantly male (60% vs 40%). At initial presentation, a broad spectrum of melanoma
stages were represented, from stage 0 to stage IV (Figure 9-1). The mean time to recurrence
for all patients in the cohort was approximately 5 years.
Seventy-eight patients (9.6%) had stage IV disease at diagnosis. Of these, 13 patients (1.6%
of the entire cohort) had distant skin metastases with normal lactate dehydrogenase levels
(M1A), 16 (2.0%) had lung metastases with normal lactate dehydrogenase levels (M1B), and
49 (6.0%) had metastases in other organs or any metastasis with high levels of lactate
dehydrogenase (M1C).
The most common sites of primary disease, regardless of initial stage at diagnosis, were
extremities (27.2%), trunk (25.9%), head (16.9%), and neck (4.8%). At the time of this study,
356 of the 810 patients (44%) had metastatic melanoma and 454 (56%) had non-metastatic
disease. In addition, 704 (87%) had resectable disease, 106 (13%) had unresectable disease,
367 (45%) had unresectable or metastatic disease, and 51 (6%) had a BRAF mutation. It
should be noted that BRAF testing was not routinely performed for most of the time period
covered by the study and that data was only available for patients with unresectable and
metastatic disease.

9.3.2 Treatment Modalities
At the time covered by this analysis, 356 of the 810 patients in the cohort had metastatic
disease, of whom 341 (95.8%) had received prior systemic therapy, and 454 patients had
non-metastatic disease, of whom 147 (32.4%) had received prior systemic therapy.
Therefore, a total of 488 (60.2%) of the 810 patients had previously received systemic
therapy at the time covered by this analysis.
Of the 367 patients with metastatic or unresectable disease at the time covered by this
analysis, 346 (94.3%) had received prior systemic therapy, including 22.3% who had
received ipilimumab, 19.9% who had received dacarbazine (DTIC) monotherapy, and 17.9%
who had received an investigational drug in a clinical trial. Most patients with unresectable
or metastatic disease had received DTIC monotherapy as first-line therapy and ipilimumab as
second- and other-line therapy (Table 9-II).
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Of the 147 patients with non-metastatic disease at presentation who had received systemic
therapy by the time of this study, 24.5% had received an investigational drug in a clinical
trial, 22.5% had received ipilimumab, and 17.7% had received DTIC monotherapy.
In all 810 patients identified, treatment modalities such as radiotherapy, surgery, and
systemic therapy had been commonly used. At the time covered by this analysis, more
patients had undergone radiotherapy (90.1%) than surgery (37.7%) or systemic therapy
(23.5%), and few patients had undergone all 3 treatments (8.9%). For the 182 patients who
presented with stage III or stage IV disease at diagnosis, both radiotherapy and surgery were
most commonly utilized.

9.3.3 Factors Affecting Survival
9.3.3.1 Unresectable or Metastatic Disease
At the time covered by this analysis, 367 patients had unresectable or metastatic disease. The
most common initial histological subtypes for patients with metastatic or unresectable
disease was superficial spreading (42.2%) and nodular (18.5%) melanoma. At the time
covered by this analysis, the proportion of patients with unresectable or metastatic disease
still alive was approximately 51%, and the estimated median survival time was 63.7 months
(95% CI, 48.3 to 79.2 months; Figure 9-2A).

9.3.3.2 Stage of Disease
Of the 182 patients who had stage III or IV disease at the time of initial diagnosis, 65% had
metastatic disease and 58% had unresectable (presence of a extranodal distant metastasis or
lymphovascular or perineural invasion) disease. The proportions of the 182 patients who had
newly diagnosed vs recurrent disease at presentation were 48% and 52%, respectively,
showing no statistical significance (P = .350). The proportion of surviving patients across
progressing disease stages decreased. At the end of the study, 79.9% of patients who initially
presented with stage 0-IIC disease were still alive, compared with 71.0% of those who
initially presented with stage III disease and 52% of those who initially presented with stage
IV disease. The median survival times by initial disease stage were 109.1 months (95% CI,
95.7 to 122.5 months), 50.8 months (95% CI, 13.6 to 88.0 months), and 33.0 months (95%
CI, 10.2 to 55.8 months) for stages 0-IIC, III, and IV, respectively (Figure 9-2B, Table 9-IV).
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The mean time to recurrence across all initial disease stages was 47.4 months (95% CI, 39.0
to 55.7 months).

9.3.3.3 BRAF Mutation Status
Of the 367 patients with unresectable or metastatic disease, 107 (29.2%) were tested for
BRAF mutations. In these unresectable metastatic patients with known BRAF mutation status,
41 (38.3%) were BRAF mutation–positive, 8 (19.5%) of which were in the stage IV M1C
classification. Of the patients who tested positive for BRAF mutation, the proportion
surviving at the study end was 83.8%, with a median survival time of 83.3 months (95% CI,
28.2 to 138.3 months; Figure 2C). The proportion of patients surviving at study end who
tested negative for BRAF mutation was 46.7%; their median survival time was 61.4 months
(95% CI, 45.4 to 77.4 months). Overall, survival for patients with unresectable metastatic
disease tested for BRAF mutation was 50.9% and the median survival time was 64.6 months
(95% CI, 48.9 to 80.3 months).
Cumulative survival decreased more steadily in patients without BRAF mutation than those
with the mutation, causing a rapid decline in survival over months (Figure 9-2C).

9.3.3.4 Brain Metastases
The brain metastasis cohort includes all patients who had brain radiotherapy. The proportion
of the 367 patients with unresectable or metastatic disease with brain metastasis was 22.9%.
Of these patients, 17.9% had brain metastasis at initial presentation 82.1% had brain
metastasis subsequently. The proportion of surviving patients with brain metastases was
50.0% at initial presentation and 50.8% at subsequent presentation. The median survival time
was 14.8 months (95% CI, 0 to 35.4 months) at presentation, and 61.2 months (95% CI, 16.4
to 106 months) subsequently. On average, patients with brain metastases had significantly
lower survival time than other patients (Figure 9-2D).

9.3.3.5 Cox Proportional Model
A Cox proportional model developed to predict survival identified stage, unknown primary
status, and brain metastases as significant predictors of survival at 1 year (Table 9-III), and
male sex as an additional adverse prognostic factor for 2-year survival (Table 9-IV).
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9.4 Discussion
The objective of this study was to provide a detailed epidemiological overview of patients
with melanoma whose data were entered into the CMRN from 3 separate cancer treatment
centres.
The population studied appears to be similar to that in other melanoma registries (eg, overall
melanoma incidence trends for sex, age, and/or disease sites). [35-41] The mean age was
58.7 years and the cohort was predominantly male (60% vs 40%). There was a broad
spectrum of initial stage representation, although there was an intentional preponderance of
patients with unresectable and metastatic disease at the time covered by this analysis. The 3
clinical investigators from whose practices the patients were principally identified are
medical oncologists and therefore tend to manage patients with advanced disease.
The molecular characterization of melanoma is proving critical in its subsequent
management. The use of BRAF testing at all 3 centres has been available outside of clinic
trials only over the past 2 years in Ontario. Consequently, the BRAF testing rate in this study
is low, 29%. Testing rates are expected to sharply increase going forward as patients are
considered for targeted therapies; it is now standard of care in Canada to test all patients with
unresectable or metastatic disease for their BRAF mutation status. In our analysis, among the
patients who underwent BRAF testing, 38.3% had BRAF-mutant tumours, which is
consistent with other epidemiological reports [35,36]. Furthermore, the availability of BRAF
inhibitors is also relatively recent, and therefore the impact of BRAF status and targeted
therapy on survival cannot be assessed in this report.
Patients with brain metastases represented another important subgroup in this study, 18% of
whom presented with brain metastasis at initial diagnosis. The overall rate of brain metastasis
in all patients with advanced disease was 23%, which is also consistent previous reports [37].
The overall survival of patients with brain metastases was significantly inferior to that of
patients without brain metastases, which underscores the importance of central nervous
system involvement as a poor prognostic factor in melanoma and the unmet need for more
effective treatments for this patient population.
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Survival rates across initial disease stages outlined in this study are congruent with rates
described in other large cohorts of patients [2,11,21,22]. In the Cox proportional model, the
study identified that stage, unknown primary status, and brain metastases were significant
predictors of survival at 1 year. For 2-year survival, male sex was an additional adverse
prognostic factor, a result that is also consistent with previous findings [38,39]. Although
other factors, such as treatment and mutational status, may potentially be important
prognostic variables, the registry has yet to be populated with sufficient numbers of patients
with adequate treatment and follow-up data to explore potential outcome variables. However,
this is expected to change as the registry is expanded to include additional patients and
lengthened follow-up information.
The primary limitation of this study is in the retrospective nature of an analysis of a limited
cohort of patients. The inclusion of patients was based on the availability of data and was not
intended to provide a comprehensive overview of all patients or of a specific subset of
patients. Patient selection was therefore intrinsically biased by data availability and was
limited to 3 geographical sites. Missing data were also an inherent problem of the study,
which relied upon the presence of information in patient records. For example, up to 103
(12.7%) of patients from the total population of 810 and 25 (6.8%) of patients from the
unresectable metastatic population of 367 were excluded from several survival analyses due
to missing values ± outliers. Furthermore, the time limits of the study reduced the ability to
observe the impact of new diagnostic and treatment modalities. The proportion of patients
who had undergone BRAF testing within the time period we observed was not as
comprehensive as we would now see.
Notwithstanding, the study allowed for detailed accounting of the demographics and clinical
outcomes of a large cohort of patients who were seen at 3 different institutions, and it also
enabled the collection of relevant data sequentially over time, providing the ability to observe
the impact of multiple sequential interventions over time.
The CMRN now includes 11 cancer treatment centres across Canada. As additional data are
collected from these 11 centres, a better treatment utilization profile will become available,
one that includes the newer agents and captures the prevalence of genomic testing. With the
increased interest in personalized medicine, the ability to link treatment to genetic testing and
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to collect prospective data will be valuable because it will allow for the comparative
evaluation of multiple agents’ effectiveness. Utilization of our patient portal to collect health
utility and health-related quality of life data will also provide a better view of the impact that
both the disease and the treatment have on cost-effectiveness.

9.5 Conclusions
This study validates the comprehensive and detailed information that can be obtained from
the CMRN Patient Registry. Although extrapolations of these findings from urban centres in
Ontario to the entire Canadian melanoma population would be premature, it appears that the
initial patient base of the CMRN registry can be extremely informative. The platform can
provide the basis for the development of a wide variety of hypotheses that can be explored
both retrospectively and prospectively. As additional data become available from other
institutions, the CMRN registry will be able to provide a better profile of the melanoma
population, including their treatments and outcomes, and will be an invaluable resource in
advancing the management of melanoma.
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Figure 9-1: Flow diagram of metastases developed during the course of disease and resectability by disease stage at initial diagnosis.
a

Comprises ocular melanoma (n = 4), no primary site determined at staging (n = 26), and stage unknown (n = 200).

b

Unresectability was defined as the presence of a distant metastasis that is extranodal or the presence of lymphovascular or perineural

invasion.
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Figure 9-2: Kaplan-Meier survival curves for (A) patients with unresectable or
metastatic disease vs all other patients in the entire cohort; (B) entire cohort by
disease stage; (C) patients with unresectable or metastatic disease by presence or
absence of BRAF mutation; and (D) patients with unresectable or metastatic disease
by presence or absence of brain metastasis.
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Table 9-1: Patient characteristics by initial stage at diagnosis
All

0

IA

IB

Total, n (%)

810

9 (1.1)

83
(10.3)

99
(12.2)

73 (9.0) 72 (8.9) 62 (7.7) 47 (5.8) 29 (3.6) 28 (3.5) 78 (9.6)

230
(28.4)

58.74
(14.78)

48.62
(13.10)

57.22
(13.99)

59.50
(14.27)

60.87
(15.71)

60.69
(14.28)

55.57
(14.37)

43 (8.9) 26 (5.4) 18 (3.7) 21 (4.3) 45 (9.3)

139
(28.7)

Age, mean
(±SD), y

IIA

IIB

63.86
(13.92)

IIC

64.18
(13.98)

IIIA

54.35
(13.72)

IIIB

58.38
(18.32)

IIIC

60.99
(15.24)

IV

Othera

Stage

Sex, n (%)
Male

485
(59.9)

3 (0.6)

41 (8.5)

56
(11.6)

40 (8.3)

Female

325
(40.1)

6 (1.9)

42
(12.9)

43
(13.2)

33
(10.2)

Time to
recurrence,
mean (±SD), y

4.94
(6.69)

0.73 (0)

7.43
(5.02)

6.69
(7.92)

3.08
(3.17)

53
(10.9)

19 (5.9) 19 (5.9) 21 (6.5) 11 (3.4)
3.13
(3.17)

7 (2.2)

33
(10.2)

91
(28.0)

2.75
(2.74)

4.29
(3.82)

2.10
(3.28)

1.59
(1.49)

3.84
(5.19)

6.40
(8.40)

4 (7.8)

4 (7.8)

2 (3.9)

11
(21.6)

12
(23.5)

Mutation type, n (%)
BRAF

51 (6.3)

0

0

0

1 (2.0)

2 (3.9)

1 (2.0)

CKIT

6 (0.7)

0

0

0

0

0

0

NRAS

1 (0.1)

0

0

0

0

0

0

1 (16.7) 1 (16.7)
0

0

0
0

1 (16.7) 3 (50.0)
0

1 (100)
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MEK

0

0

0

0

0

0

0

0

0

0

0

0

GNAO

0

0

0

0

0

0

0

0

0

0

0

0

GNA11

0

0

0

0

0

0

0

0

0

0

0

0

78
(21.9)

121
(34.0)

0

109
(24.0)

0

0

230
(32.7)

28
(26.4)

78
(73.6)

0

Metastatic status, n (%)
Metastatic

356
(44.0)

1 (0.3)

Non metastatic

454
(56.1)

8 (1.8)

18 (5.1) 31 (8.7) 16 (4.5) 26 (7.3) 25 (7.0) 10 (2.8) 13 (3.7) 17 (4.8)
65
(14.3)

68
(15.0)

57
(12.6)

46
(10.1)

37 (8.1) 37 (8.1) 16 (3.5) 11 (2.4)

Resectability status, n (%)

a

Resectable

704
(86.9)

9 (1.3)

83
(11.8)

99
(14.1)

73
(10.4)

72
(10.2)

Unresectable

106
(13.1)

0

0

0

0

0

62 (8.8) 47 (6.7) 29 (4.1)
0

0

0

Comprises ocular melanoma (n = 4, 0.5%), no primary site determined at staging (n = 26, 3.2%), and stage unknown (n = 200, 24.7%).
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Table 9-2: Number of patients with unresectable or metastatic disease utilizing
treatment modalities by line of treatment

Line of Therapy, n (%)
Treatments

First Line

Second Line

Other

n = 346

n = 210

n = 107

n = 29

Abraxane

2 (0.95)

1 (0.93)

1 (3.45)

Carboplatin + paclitaxel

35 (16.67)

14 (13.08)

6 (20.69)

Clinical trial

44 (20.95)

13 (12.15)

5 (17.24)

DTIC + cisplatin

10 (4.76)

5 (4.67)

0

0

1 (0.93)

0

58 (27.62)

9 (8.41)

2 (6.9)

0

1 (0.93)

0

24 (11.43)

43 (40.19)

10 (34.48)

Paclitaxel

1 (0.48)

0

0

Temozolomide

9 (4.29)

3 (2.8)

1 (3.45)

23 (10.95)

9 (8.41)

1 (3.45)

Other

1 (0.48)

4 (3.74)

2 (6.9)

Unknown

3 (1.43)

4 (3.74)

1 (3.45)

DTIC + cisplatin + tamoxifen
DTIC alone
Imatinib
Ipilimumab

Vemurafenib

DTIC, dacarbazine.

117

Table 9-3: Variables in the Cox proportional model for survival at 1 year
95% CI

Variable

Lower

Upper

coef

exp(coef)

se(coef)

z

Pr(>|z|)

Bound

Bound

Stage 0

1.45E+00

4.26E+00

6.88E-01

2.105

0.035276

1.10511

16.41

Stage IA

1.54E+00

4.67E+00

4.22E-01

3.649

0.000264

2.03997

10.675

Stage IB

1.38E+00

3.97E+00

4.07E-01

3.389

0.000701

1.78802

8.8

Stage IIA

1.37E+00

3.95E+00

4.52E-01

3.036

0.002395

1.62729

9.586

Stage IIB

9.51E-01

2.59E+00

4.69E-01

2.029

0.042466

1.03285

6.485

Stage IIC

2.96E-01

1.35E+00

4.98E-01

0.595

0.551885

0.50682

3.568

Stage IIIA

6.23E-01

1.87E+00

6.90E-01

0.903

0.366291

0.48238

7.213

Stage IIIB

-5.19E-01

5.95E-01

7.98E-01

-0.65

0.515434

0.12452

2.844

Stage IIIC

-1.40E+00

2.47E-01

1.06E+00 -1.315 0.188404

0.03073

1.985

Other at staging

-3.57E-01

7.00E-01

1.07E+00 -0.334 0.738226

0.08646

5.668

Stage IV

-9.47E-01

3.88E-01

5.74E-01

0.12592

1.196

PUK at staging

-1.58E+01

1.40E-07

3.03E+03 -0.005 0.995848

0

Inf

Sex (Male)

-3.32E-01

7.18E-01

1.96E-01

0.48862

1.054

Inf, infinity; PUK, unknown primary status.

-1.649 0.099194

-1.694 0.090347
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Table 9-4: Variables in the Cox proportional model for survival at 2 years
95% CI

Variable

coef

exp(coef) se(coef)

Stage 0

1.902

6.6993

Stage IA

1.8446

Stage IB

Lower

Upper

z

Pr(>|z|)

Bound

Bound

0.5735

3.317

0.000911

2.17717

20.614

6.3255

0.323

5.711

1.12E-08

3.35858

11.913

1.5345

4.6389

0.3136

4.893

9.94E-07

2.50879

8.578

Stage IIA

1.1826

3.2627

0.3426

3.452

0.000556

1.6672

6.385

Stage IIB

0.9165

2.5005

0.3493

2.624

0.008699

1.26093

4.959

Stage IIC

0.3141

1.369

0.4045

0.776

0.437478

0.61959

3.025

Stage IIIA

0.6687

1.9518

0.428

1.562

0.118219

0.84348

4.516

Stage IIIB

0.5425

1.7202

0.4648

1.167

0.243145

0.6918

4.278

Stage IIIC

-1.744

0.1748

1.0355

-1.684 0.092141

0.02297

1.33

Other at staging

-0.4679

0.6263

1.0357

-0.452 0.651414

0.08226

4.768

Stage IV

-0.3465

0.7072

0.4644

-0.746 0.455613

0.28461

1.757

Ocular at staging

0.9495

2.5845

1.0417

0.912

0.362017

0.3355

19.91

PUK at staging

0.6024

1.8266

0.6393

0.942

0.345997

0.52178

6.394

Sex (Male)

-0.1018

0.9032

0.1619

-0.629 0.529615

0.65763

1.241

PUK, unknown primary status.
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Chapter 10
10 Concluding Thoughts
Throughout this thesis, several published articles have been examined to represent my
transition from basic sciences research to clinical informatics research. In one way or
another, the techniques described build on each other, and have fostered the nurturing of my
skills to continue in the world of clinical informatics.
In the research of basic sciences, I began with the use of ultrasound imaging to present novel
techniques in the segmentation of left ventricular function, the representation of tissue
characterization, and the accurate measure of ejection fraction. These techniques leverage
fundamental algorithms in active contouring, optical flow mechanics, and A-prior knowledge
representation. I have shown that these novel techniques have made a quantitative
improvement over the original methodologies presented and have made an impact in the
research community. These articles have cumulatively been referenced 35 times.
Leveraging the medical understanding garnered in the basic science investigations, I
branched off into clinical informatics studies, where I was able to accurately create models
for representing and predicting Sepsis patients and Alzheimer’s Disease patients. These
studies were constructed on the foundations of cluster analysis, the use of decision tree
generation, and hidden Markov modelling. Following this, I designed an efficient data
capture model for progressive and chronic diseases, specifically Melanoma. This platform
collects data directly from patients and clinicians, leverages external heterogeneous data sets,
and allows for the meaningful extraction of information in real-time. As a result, the use of
this model currently allows for meaningful studies to be disseminated in relative short order,
as other researchers are now publishing using the resulting datasets.

124

10.1 Transition
The transition from basic science research to clinical informatics was an arduous and
evolutionary learning experience. Initially, my sentiment towards all clinical research was
one of deficiency and it genuinely not deserving the label “research contribution.” It is very
apparent to me how wrong I was. Clinical informatics research is absolutely fundamental to
the betterment of our society at large, and is in fact, a research tract that is critical to the
academic continuum or pathway. If anything, clinical informatics research is the key way of
applying fundamental basic science research efficiently to real world situations (in the cases
presented above for clinical practice guidelines and the improvement of patient care). It is not
simply the teasing of data sets for scholarly purposes, rather, it takes ingenuity and insight to
understand what quantifiable data sets represent and why they are yielding results in a
clinical capacity.
The paradigm shift to the world of clinical informatics has provided an introspective change
on how I personally conduct my research today. Through this transition, a fundamental
‘stepping stone’ to better research understanding was provided. I believe that this provides a
greater level of respect for the time and effort that is spent on studies that present the
essential foundations for all future work. When I began this journey, the idea of interpreting
my results based on arbitrary clinical impact or a practice guideline was foreign to me. I now
know, that such research impacts real-world treatment patterns and helps to create models
that provide predictions for interventions of care. This could potentially improve the quality
of life of a patient or even save that life. This was the change that I wanted to be a part of and
will continue to contribute to.
Now that my transition is complete, I will continue on this research tract and do my utmost to
positively impact the world around me.

10.2 Future Outlook
The clinical informatics research presented in this thesis was based on fundamental
mathematical models, that are in essence, basic research outcomes, applied in novel ways to
deal with the real-world problems needing efficient solutions. Rather than continue to try and
apply these models to several other disease domains, there is a genuine need to improve the
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capture of data at its inception. This data is generated from patients, clinicians, laboratory
tests, wearables, procedural outcomes, and a horde of other heterogeneous sources which all
live in silos. This creates a seemingly overwhelming problem of how to consolidate and
harmonize data sets without losing a large amount of granularity in the process. This
heterogeneous data problem, if solved, can provide a multitude of useful information where
silos are broken down in order to provide real guidance on patient outcomes and
improvement of care.
As shown, I have already started to embark on this line of multidisciplinary research, and
publishing works on disease costing and impact, effective data collection and deeper
pipelines of clinical outcomes. This work includes elements from human computer
interaction exploration for efficient visual interfaces, ontological language generation for data
harmonization, and naturally, clinical domain knowledge for the speciality itself. I intend to
continue on this research tract, as I believe it will have a great impact on the ever rich and
growing data world.
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